

# Gordon B Mills

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/2463874/gordon-b-mills-publications-by-citations.pdf>

**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

821  
papers

118,538  
citations

164  
h-index

326  
g-index

873  
ext. papers

147,044  
ext. citations

11.9  
avg, IF

8.11  
L-index

#	Paper	IF	Citations
821	The Cancer Genome Atlas Pan-Cancer analysis project. <i>Nature Genetics</i> , <b>2013</b> , 45, 1113-20	36.3	3933
820	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). <i>Autophagy</i> , <b>2016</b> , 12, 1-222	10.2	3838
819	The somatic genomic landscape of glioblastoma. <i>Cell</i> , <b>2013</b> , 155, 462-77	56.2	2900
818	Integrated genomic characterization of endometrial carcinoma. <i>Nature</i> , <b>2013</b> , 497, 67-73	50.4	2800
817	Use of proteomic patterns in serum to identify ovarian cancer. <i>Lancet, The</i> , <b>2002</b> , 359, 572-7	40	2653
816	Inferring tumour purity and stromal and immune cell admixture from expression data. <i>Nature Communications</i> , <b>2013</b> , 4, 2612	17.4	2572
815	mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. <i>Cancer Research</i> , <b>2006</b> , 66, 1500-8	10.1	2114
814	Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. <i>New England Journal of Medicine</i> , <b>2015</b> , 372, 2481-98	59.2	1828
813	The Immune Landscape of Cancer. <i>Immunity</i> , <b>2018</b> , 48, 812-830.e14	32.3	1754
812	Integrated genomic characterization of papillary thyroid carcinoma. <i>Cell</i> , <b>2014</b> , 159, 676-90	56.2	1660
811	Exploiting the PI3K/AKT pathway for cancer drug discovery. <i>Nature Reviews Drug Discovery</i> , <b>2005</b> , 4, 988-1004	10.4	1618
810	Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. <i>Nature Medicine</i> , <b>2011</b> , 17, 1498-503	50.5	1295
809	A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. <i>Cancer Cell</i> , <b>2007</b> , 12, 395-402	24.3	1282
808	Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma. <i>Cell</i> , <b>2017</b> , 169, 1327-1341.e23	56.2	1125
807	Oncogenic Signaling Pathways in The Cancer Genome Atlas. <i>Cell</i> , <b>2018</b> , 173, 321-337.e10	56.2	1124
806	An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics. <i>Cell</i> , <b>2018</b> , 173, 400-416.e11	56.2	1072
805	Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. <i>Nature</i> , <b>2018</b> , 560, 382-386	50.4	1058

804	Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer. <i>Cell</i> , <b>2015</b> , 163, 506-19	56.2	1055
803	Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. <i>Nature Genetics</i> , <b>2008</b> , 40, 616-22	36.3	1036
802	Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling. <i>Cell</i> , <b>2012</b> , 150, 780-91	56.2	1028
801	The biology of ovarian cancer: new opportunities for translation. <i>Nature Reviews Cancer</i> , <b>2009</b> , 9, 415-28	31.3	1024
800	Next-generation characterization of the Cancer Cell Line Encyclopedia. <i>Nature</i> , <b>2019</b> , 569, 503-508	50.4	962
799	Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer. <i>Cell</i> , <b>2017</b> , 171, 540-556.e75	56.2	961
798	PIK3CA is implicated as an oncogene in ovarian cancer. <i>Nature Genetics</i> , <b>1999</b> , 21, 99-102	36.3	955
797	Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. <i>Cell</i> , <b>2014</b> , 158, 929-944	56.2	935
796	The emerging role of lysophosphatidic acid in cancer. <i>Nature Reviews Cancer</i> , <b>2003</b> , 3, 582-91	31.3	903
795	Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma. <i>Cancer Cell</i> , <b>2017</b> , 32, 185-203.e13	56.2	896
794	Rethinking ovarian cancer: recommendations for improving outcomes. <i>Nature Reviews Cancer</i> , <b>2011</b> , 11, 719-25	31.3	893
793	Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer. <i>Cell</i> , <b>2018</b> , 173, 291-304.e6	56.2	888
792	Comprehensive Characterization of Cancer Driver Genes and Mutations. <i>Cell</i> , <b>2018</b> , 173, 371-385.e18	56.2	854
791	Pan-cancer analysis of whole genomes. <i>Nature</i> , <b>2020</b> , 578, 82-93	50.4	840
790	An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. <i>Cancer Research</i> , <b>2008</b> , 68, 6084-91	10.1	806
789	Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. <i>Journal of Cell Biology</i> , <b>2002</b> , 158, 227-33	7.3	763
788	Integrated genomic and molecular characterization of cervical cancer. <i>Nature</i> , <b>2017</b> , 543, 378-384	50.4	755
787	Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , <b>2016</b> , 374, 135-45	59.2	753

786	The energy sensing LKB1-AMPK pathway regulates p27(kip1) phosphorylation mediating the decision to enter autophagy or apoptosis. <i>Nature Cell Biology</i> , <b>2007</b> , 9, 218-24	23.4	704
785	Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. <i>Cancer Research</i> , <b>2009</b> , 69, 4116-24	10.1	674
784	Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 1688-98	12.9	659
783	An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. <i>Clinical Cancer Research</i> , <b>2013</b> , 19, 279-90	12.9	649
782	Phosphorylation of beta-catenin by AKT promotes beta-catenin transcriptional activity. <i>Journal of Biological Chemistry</i> , <b>2007</b> , 282, 11221-9	5.4	637
781	Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation. <i>Cell</i> , <b>2018</b> , 173, 338-354.e15	56.2	560
780	Derailed endocytosis: an emerging feature of cancer. <i>Nature Reviews Cancer</i> , <b>2008</b> , 8, 835-50	31.3	548
779	ATM signals to TSC2 in the cytoplasm to regulate mTORC1 in response to ROS. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2010</b> , 107, 4153-8	11.5	532
778	Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells. <i>Molecular Cancer Therapeutics</i> , <b>2006</b> , 5, 2512-21	6.1	526
777	ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation. <i>Nature Cell Biology</i> , <b>2008</b> , 10, 138-48	23.4	515
776	Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. <i>Cancer Discovery</i> , <b>2015</b> , 5, 860-77	24.4	476
775	Synergistic augmentation of rapamycin-induced autophagy in malignant glioma cells by phosphatidylinositol 3-kinase/protein kinase B inhibitors. <i>Cancer Research</i> , <b>2005</b> , 65, 3336-46	10.1	471
774	Comprehensive Genomic Characterization of Long Non-coding RNAs across Human Cancers. <i>Cancer Cell</i> , <b>2015</b> , 28, 529-540	24.3	465
773	Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas. <i>Cell</i> , <b>2017</b> , 171, 950-965.e28	56.2	451
772	Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. <i>Cell Reports</i> , <b>2013</b> , 4, 1116-30	10.6	447
771	Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 3764-73	12.9	438
770	AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. <i>Cancer Cell</i> , <b>2009</b> , 16, 21-32	24.3	432
769	Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers. <i>Cancer Discovery</i> , <b>2013</b> , 3, 761-9	24.4	414

768	The RAB25 small GTPase determines aggressiveness of ovarian and breast cancers. <i>Nature Medicine</i> , <b>2004</b> , 10, 1251-6	50.5	412
767	State-of-the-art strategies for targeting the DNA damage response in cancer. <i>Nature Reviews Clinical Oncology</i> , <b>2019</b> , 16, 81-104	19.4	412
766	Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. <i>Oncogene</i> , <b>2003</b> , 22, 2812-22	9.2	409
765	Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 1082-9	12.9	407
764	Protein kinase B (PKB/Akt) activity is elevated in glioblastoma cells due to mutation of the tumor suppressor PTEN/MMAC. <i>Current Biology</i> , <b>1998</b> , 8, 1195-8	6.3	407
763	Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas. <i>Cell Reports</i> , <b>2018</b> , 23, 239-254.e6	10.6	405
762	Validation of an anti-sphingosine-1-phosphate antibody as a potential therapeutic in reducing growth, invasion, and angiogenesis in multiple tumor lineages. <i>Cancer Cell</i> , <b>2006</b> , 9, 225-38	24.3	396
761	A module of negative feedback regulators defines growth factor signaling. <i>Nature Genetics</i> , <b>2007</b> , 39, 503-12	36.3	394
760	Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma. <i>Cancer Cell</i> , <b>2017</b> , 32, 204-220.e15	24.3	391
759	Genomic and Functional Approaches to Understanding Cancer Aneuploidy. <i>Cancer Cell</i> , <b>2018</b> , 33, 676-689.e3	24.3	377
758	Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer. <i>Journal of Clinical Investigation</i> , <b>2010</b> , 120, 2406-13	15.9	375
757	HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. <i>Oncogene</i> , <b>2003</b> , 22, 3205-12	9.2	369
756	Spatial Organization and Molecular Correlation of Tumor-Infiltrating Lymphocytes Using Deep Learning on Pathology Images. <i>Cell Reports</i> , <b>2018</b> , 23, 181-193.e7	10.6	366
755	Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. <i>Clinical Cancer Research</i> , <b>2004</b> , 10, 3291-300	12.9	358
754	Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma. <i>Cancer Cell</i> , <b>2017</b> , 31, 181-193	24.3	350
753	Subtype and pathway specific responses to anticancer compounds in breast cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2012</b> , 109, 2724-9	11.5	347
752	Pathogenic Germline Variants in 10,389 Adult Cancers. <i>Cell</i> , <b>2018</b> , 173, 355-370.e14	56.2	342
751	High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability. <i>Cancer Discovery</i> , <b>2011</b> , 1, 170-85	24.4	342

750	PKM2 isoform-specific deletion reveals a differential requirement for pyruvate kinase in tumor cells. <i>Cell</i> , <b>2013</b> , 155, 397-409	56.2	333
749	A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models. <i>Cancer Research</i> , <b>2013</b> , 73, 4885-97	10.1	331
748	Rab25 associates with alpha5beta1 integrin to promote invasive migration in 3D microenvironments. <i>Developmental Cell</i> , <b>2007</b> , 13, 496-510	10.2	330
747	Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients. <i>Cancer Cell</i> , <b>2018</b> , 34, 211-224.e6	24.3	327
746	A pan-cancer proteomic perspective on The Cancer Genome Atlas. <i>Nature Communications</i> , <b>2014</b> , 5, 3887-91	17.4	324
745	Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. <i>Cancer Discovery</i> , <b>2012</b> , 2, 798-811	24.4	323
744	Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines. <i>Cell Systems</i> , <b>2018</b> , 6, 271-281.e7	10.6	320
743	Frequency-modulated pulses of ERK activity transmit quantitative proliferation signals. <i>Molecular Cell</i> , <b>2013</b> , 49, 249-61	17.6	317
742	Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached cancer cells. <i>Cancer Cell</i> , <b>2012</b> , 21, 227-39	24.3	309
741	Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition. <i>Cancer Research</i> , <b>2009</b> , 69, 565-72	10.1	304
740	A functional genomic approach identifies FAL1 as an oncogenic long noncoding RNA that associates with BMI1 and represses p21 expression in cancer. <i>Cancer Cell</i> , <b>2014</b> , 26, 344-357	24.3	303
739	Amplification of PVT1 contributes to the pathophysiology of ovarian and breast cancer. <i>Clinical Cancer Research</i> , <b>2007</b> , 13, 5745-55	12.9	301
738	Expression of autotaxin and lysophosphatidic acid receptors increases mammary tumorigenesis, invasion, and metastases. <i>Cancer Cell</i> , <b>2009</b> , 15, 539-50	24.3	299
737	The tumor suppressor gene ARHI regulates autophagy and tumor dormancy in human ovarian cancer cells. <i>Journal of Clinical Investigation</i> , <b>2008</b> , 118, 3917-29	15.9	298
736	Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 2753-62	2.2	295
735	The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. <i>Cell Reports</i> , <b>2018</b> , 23, 313-326.e5	10.6	295
734	PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2010</b> , 107, 10208-13	11.5	293
733	Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 3570-6	2.2	290

732	Growth of triple-negative breast cancer cells relies upon coordinate autocrine expression of the proinflammatory cytokines IL-6 and IL-8. <i>Cancer Research</i> , <b>2013</b> , 73, 3470-80	10.1	289
731	TCPA: a resource for cancer functional proteomics data. <i>Nature Methods</i> , <b>2013</b> , 10, 1046-7	21.6	288
730	A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations. <i>Cancer Cell</i> , <b>2017</b> , 31, 820-832.e3	24.3	286
729	Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells. <i>Clinical Cancer Research</i> , <b>2004</b> , 10, 7031-42	12.9	280
728	The Genomic Landscape and Clinical Relevance of A-to-I RNA Editing in Human Cancers. <i>Cancer Cell</i> , <b>2015</b> , 28, 515-528	24.3	278
727	A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers. <i>Cancer Cell</i> , <b>2018</b> , 33, 690-705.e9	24.3	277
726	Sustained activation of JNK/p38 MAPK pathways in response to cisplatin leads to Fas ligand induction and cell death in ovarian carcinoma cells. <i>Journal of Biological Chemistry</i> , <b>2003</b> , 278, 19245-56	5.4	276
725	Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications. <i>PLoS ONE</i> , <b>2014</b> , 9, e115383	3.7	276
724	lncRNA Epigenetic Landscape Analysis Identifies EPIC1 as an Oncogenic lncRNA that Interacts with MYC and Promotes Cell-Cycle Progression in Cancer. <i>Cancer Cell</i> , <b>2018</b> , 33, 706-720.e9	24.3	275
723	Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer. <i>Nature Genetics</i> , <b>2009</b> , 41, 991-5	36.3	270
722	Cancer stem cells contribute to cisplatin resistance in Brca1/p53-mediated mouse mammary tumors. <i>Cancer Research</i> , <b>2008</b> , 68, 3243-50	10.1	262
721	The PTEN/MMAC1/TEP tumor suppressor gene decreases cell growth and induces apoptosis and anoikis in breast cancer cells. <i>Oncogene</i> , <b>1999</b> , 18, 7034-45	9.2	261
720	ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors. <i>Cancer Discovery</i> , <b>2015</b> , 5, 752-67	24.4	260
719	Functional Genomic Landscape of Human Breast Cancer Drivers, Vulnerabilities, and Resistance. <i>Cell</i> , <b>2016</b> , 164, 293-309	56.2	259
718	Integrative Molecular Characterization of Malignant Pleural Mesothelioma. <i>Cancer Discovery</i> , <b>2018</b> , 8, 1548-1565	24.4	258
717	The chemokine growth-regulated oncogene 1 (Gro-1) links RAS signaling to the senescence of stromal fibroblasts and ovarian tumorigenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2006</b> , 103, 16472-7	11.5	256
716	Determinants of rapamycin sensitivity in breast cancer cells. <i>Clinical Cancer Research</i> , <b>2004</b> , 10, 1013-23	12.9	254
715	MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition. <i>Journal of Experimental Medicine</i> , <b>2012</b> , 209, 679-96	16.6	252

714	Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance. <i>Cancer Research</i> , <b>2009</b> , 69, 143-50	10.1	250
713	A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity. <i>Cancer Research</i> , <b>2008</b> , 68, 206-15	10.1	250
712	Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon. <i>Clinical Cancer Research</i> , <b>2005</b> , 11, 6116-26	12.9	250
711	Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles. <i>Cell Reports</i> , <b>2017</b> , 18, 2780-2794	10.6	247
710	Use of reverse phase protein microarrays and reference standard development for molecular network analysis of metastatic ovarian carcinoma. <i>Molecular and Cellular Proteomics</i> , <b>2005</b> , 4, 346-55	7.6	244
709	ER-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer. <i>Cancer Discovery</i> , <b>2011</b> , 1, 338-51	24.4	242
708	Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. <i>Molecular and Cellular Proteomics</i> , <b>2014</b> , 13, 1690-704	7.6	239
707	Driver Fusions and Their Implications in the Development and Treatment of Human Cancers. <i>Cell Reports</i> , <b>2018</b> , 23, 227-238.e3	10.6	235
706	Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward. <i>Clinical Cancer Research</i> , <b>2006</b> , 12, 3661-97	12.9	235
705	Inhibition of phosphatidylinositol 3'-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. <i>Cancer Research</i> , <b>2002</b> , 62, 1087-92	10.1	234
704	A genetically defined model for human ovarian cancer. <i>Cancer Research</i> , <b>2004</b> , 64, 1655-63	10.1	233
703	Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas. <i>Cancer Cell</i> , <b>2018</b> , 33, 721-735.e8	24.3	228
702	Multilevel Genomics-Based Taxonomy of Renal Cell Carcinoma. <i>Cell Reports</i> , <b>2016</b> , 14, 2476-89	10.6	228
701	ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. <i>Nature Medicine</i> , <b>2018</b> , 24, 556-562	50.5	227
700	Targeting the hepatocyte growth factor-cMET axis in cancer therapy. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 3287-96	2.2	226
699	Regulation of BAD phosphorylation at serine 112 by the Ras-mitogen-activated protein kinase pathway. <i>Oncogene</i> , <b>1999</b> , 18, 6635-40	9.2	226
698	Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers. <i>Molecular Carcinogenesis</i> , <b>2008</b> , 47, 701-6	5	218
697	PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness. <i>Cancer Research</i> , <b>2019</b> , 79, 311-319	10.1	217



696	Markedly elevated levels of vascular endothelial growth factor in malignant ascites. <i>Annals of Surgical Oncology</i> , <b>1999</b> , 6, 373-8	3.1	212
695	Integrated Molecular Characterization of Uterine Carcinosarcoma. <i>Cancer Cell</i> , <b>2017</b> , 31, 411-423	24.3	210
694	A new mutational AKTivation in the PI3K pathway. <i>Cancer Cell</i> , <b>2007</b> , 12, 104-7	24.3	210
693	Atypical PKC $\alpha$ contributes to poor prognosis through loss of apical-basal polarity and cyclin E overexpression in ovarian cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2005</b> , 102, 12519-24	11.5	206
692	Assessing the clinical utility of cancer genomic and proteomic data across tumor types. <i>Nature Biotechnology</i> , <b>2014</b> , 32, 644-52	44.5	205
691	Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents. <i>Clinical Cancer Research</i> , <b>2013</b> , 19, 657-67	12.9	205
690	Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway-dependent and PI3K pathway-independent mechanisms. <i>Nature Medicine</i> , <b>2011</b> , 17, 1116-20	50.5	205
689	Modeling precision treatment of breast cancer. <i>Genome Biology</i> , <b>2013</b> , 14, R110	18.3	204
688	Lysophosphatidic acid induction of vascular endothelial growth factor expression in human ovarian cancer cells. <i>Journal of the National Cancer Institute</i> , <b>2001</b> , 93, 762-8	9.7	204
687	Integrated Molecular Characterization of Testicular Germ Cell Tumors. <i>Cell Reports</i> , <b>2018</b> , 23, 3392-3406	10.6	200
686	The Library of Integrated Network-Based Cellular Signatures NIH Program: System-Level Cataloging of Human Cells Response to Perturbations. <i>Cell Systems</i> , <b>2018</b> , 6, 13-24	10.6	199
685	PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors. <i>Breast Cancer Research</i> , <b>2014</b> , 16, 406	8.3	199
684	The PI3K/AKT Pathway and Renal Cell Carcinoma. <i>Journal of Genetics and Genomics</i> , <b>2015</b> , 42, 343-53	4	197
683	Future of personalized medicine in oncology: a systems biology approach. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 2777-83	2.2	195
682	Functional proteomic profiling of AML predicts response and survival. <i>Blood</i> , <b>2009</b> , 113, 154-64	2.2	195
681	Tyrosine phosphorylation of p85 relieves its inhibitory activity on phosphatidylinositol 3-kinase. <i>Journal of Biological Chemistry</i> , <b>2001</b> , 276, 27455-61	5.4	194
680	Lysophospholipid growth factors in the initiation, progression, metastases, and management of ovarian cancer. <i>Annals of the New York Academy of Sciences</i> , <b>2000</b> , 905, 188-208	6.5	192
679	AMPK: a contextual oncogene or tumor suppressor?. <i>Cancer Research</i> , <b>2013</b> , 73, 2929-35	10.1	191

678	Src family protein-tyrosine kinases alter the function of PTEN to regulate phosphatidylinositol 3-kinase/AKT cascades. <i>Journal of Biological Chemistry</i> , <b>2003</b> , 278, 40057-66	5.4	189
677	Somatic Mutational Landscape of Splicing Factor Genes and Their Functional Consequences across 33 Cancer Types. <i>Cell Reports</i> , <b>2018</b> , 23, 282-296.e4	10.6	188
676	Dual inhibition of tumor energy pathway by 2-deoxyglucose and metformin is effective against a broad spectrum of preclinical cancer models. <i>Molecular Cancer Therapeutics</i> , <b>2011</b> , 10, 2350-62	6.1	188
675	Insulin-like growth factor-I inhibits progesterone receptor expression in breast cancer cells via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway: progesterone receptor as a potential indicator of growth factor activity in breast cancer. <i>Molecular Endocrinology</i> , <b>2003</b> , 17, 575-88		186
674	Astrocytes upregulate survival genes in tumor cells and induce protection from chemotherapy. <i>Neoplasia</i> , <b>2011</b> , 13, 286-98	6.4	184
673	Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma. <i>Clinical Cancer Research</i> , <b>2009</b> , 15, 7538-7546	12.9	184
672	Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer. <i>Breast Cancer Research</i> , <b>2010</b> , 12, R40	8.3	182
671	PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer. <i>Molecular Cancer Therapeutics</i> , <b>2011</b> , 10, 1093-101	6.1	181
670	Whole-exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer. <i>Genome Research</i> , <b>2012</b> , 22, 2120-9	9.7	178
669	Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance. <i>Nature Medicine</i> , <b>2012</b> , 18, 1052-9	50.5	177
668	Induction of human MDR1 gene expression by 2-acetylaminofluorene is mediated by effectors of the phosphoinositide 3-kinase pathway that activate NF-kappaB signaling. <i>Oncogene</i> , <b>2002</b> , 21, 1945-54	9.2	177
667	Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency. <i>Clinical Cancer Research</i> , <b>2007</b> , 13, 5883-8	12.9	176
666	Emerging role of RAB GTPases in cancer and human disease. <i>Cancer Research</i> , <b>2005</b> , 65, 2516-9	10.1	176
665	PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors. <i>Clinical Cancer Research</i> , <b>2012</b> , 18, 1777-89	12.9	174
664	Autotaxin hydrolyzes sphingosylphosphorylcholine to produce the regulator of migration, sphingosine-1-phosphate. <i>Cancer Research</i> , <b>2003</b> , 63, 5446-53	10.1	174
663	A Technical Assessment of the Utility of Reverse Phase Protein Arrays for the Study of the Functional Proteome in Non-microdissected Human Breast Cancers. <i>Clinical Proteomics</i> , <b>2010</b> , 6, 129-51	5	170
662	Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer. <i>Clinical Cancer Research</i> , <b>2009</b> , 15, 2472-8	12.9	169
661	Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors. <i>Journal of Clinical Investigation</i> , <b>2016</b> , 126, 1834-56	15.9	167

660	Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics. <i>Cell</i> , <b>2018</b> , 173, 305-320.e10	56.2	166
659	Non-parametric quantification of protein lysate arrays. <i>Bioinformatics</i> , <b>2007</b> , 23, 1986-94	7.2	164
658	Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates. <i>Molecular Cancer Therapeutics</i> , <b>2009</b> , 8, 2079-85	6.1	163
657	Identification of optimal drug combinations targeting cellular networks: integrating phospho-proteomics and computational network analysis. <i>Cancer Research</i> , <b>2010</b> , 70, 6704-14	10.1	161
656	Gain-of-function mutant p53 promotes cell growth and cancer cell metabolism via inhibition of AMPK activation. <i>Molecular Cell</i> , <b>2014</b> , 54, 960-74	17.6	160
655	Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas. <i>Cell Systems</i> , <b>2018</b> , 6, 282-300.e2	10.6	159
654	Inferring causal molecular networks: empirical assessment through a community-based effort. <i>Nature Methods</i> , <b>2016</b> , 13, 310-8	21.6	158
653	Inhibition of the phosphatidylinositol 3'-kinase-AKT pathway induces apoptosis in pancreatic carcinoma cells in vitro and in vivo. <i>Molecular Cancer Therapeutics</i> , <b>2002</b> , 1, 989-97	6.1	158
652	Activation of integrin-linked kinase is a critical prosurvival pathway induced in leukemic cells by bone marrow-derived stromal cells. <i>Cancer Research</i> , <b>2007</b> , 67, 684-94	10.1	156
651	Mechanisms for lysophosphatidic acid-induced cytokine production in ovarian cancer cells. <i>Journal of Biological Chemistry</i> , <b>2004</b> , 279, 9653-61	5.4	153
650	Multiplex digital spatial profiling of proteins and RNA in fixed tissue. <i>Nature Biotechnology</i> , <b>2020</b> , 38, 586-599	44.5	152
649	Rak functions as a tumor suppressor by regulating PTEN protein stability and function. <i>Cancer Cell</i> , <b>2009</b> , 15, 304-14	24.3	152
648	Comprehensive Molecular Characterization of the Hippo Signaling Pathway in Cancer. <i>Cell Reports</i> , <b>2018</b> , 25, 1304-1317.e5	10.6	152
647	Comprehensive Characterization of Molecular Differences in Cancer between Male and Female Patients. <i>Cancer Cell</i> , <b>2016</b> , 29, 711-722	24.3	151
646	The Integrated Genomic Landscape of Thymic Epithelial Tumors. <i>Cancer Cell</i> , <b>2018</b> , 33, 244-258.e10	24.3	150
645	Activated SRC protein tyrosine kinase is overexpressed in late-stage human ovarian cancers. <i>Gynecologic Oncology</i> , <b>2003</b> , 88, 73-9	4.9	150
644	Trastuzumab has preferential activity against breast cancers driven by HER2 homodimers. <i>Cancer Research</i> , <b>2011</b> , 71, 1871-82	10.1	149
643	Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context. <i>Cell Reports</i> , <b>2018</b> , 23, 297-312.e12	10.6	147

642	Convergence of multiple signaling cascades at glycogen synthase kinase 3: Edg receptor-mediated phosphorylation and inactivation by lysophosphatidic acid through a protein kinase C-dependent intracellular pathway. <i>Molecular and Cellular Biology</i> , <b>2002</b> , 22, 2099-110	4.8	147
641	Comparison of Breast Cancer Molecular Features and Survival by African and European Ancestry in The Cancer Genome Atlas. <i>JAMA Oncology</i> , <b>2017</b> , 3, 1654-1662	13.4	146
640	Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas. <i>Cell Reports</i> , <b>2018</b> , 23, 194-212.e6	10.6	146
639	Proteomic markers of DNA repair and PI3K pathway activation predict response to the PARP inhibitor BMN 673 in small cell lung cancer. <i>Clinical Cancer Research</i> , <b>2013</b> , 19, 6322-8	12.9	144
638	Lineage infidelity of MDA-MB-435 cells: expression of melanocyte proteins in a breast cancer cell line. <i>Cancer Research</i> , <b>2004</b> , 64, 3479-85	10.1	144
637	Loss of Phosphatase and Tensin homologue deleted on chromosome 10 engages ErbB3 and insulin-like growth factor-I receptor signaling to promote antiestrogen resistance in breast cancer. <i>Cancer Research</i> , <b>2009</b> , 69, 4192-201	10.1	142
636	The Human Tumor Atlas Network: Charting Tumor Transitions across Space and Time at Single-Cell Resolution. <i>Cell</i> , <b>2020</b> , 181, 236-249	56.2	140
635	Characterization of Human Cancer Cell Lines by Reverse-phase Protein Arrays. <i>Cancer Cell</i> , <b>2017</b> , 31, 225-239	23.9	139
634	BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency. <i>Cancer Cell</i> , <b>2018</b> , 33, 401-416.e8	24.3	138
633	Genome-wide transcriptome profiling of homologous recombination DNA repair. <i>Nature Communications</i> , <b>2014</b> , 5, 3361	17.4	137
632	Akt1 and akt2 play distinct roles in the initiation and metastatic phases of mammary tumor progression. <i>Cancer Research</i> , <b>2009</b> , 69, 5057-64	10.1	136
631	Interleukin-2 induces proliferation of T lymphocyte mutants lacking protein kinase C. <i>Cell</i> , <b>1988</b> , 55, 91-100	10.2	136
630	A decision support framework for genomically informed investigational cancer therapy. <i>Journal of the National Cancer Institute</i> , <b>2015</b> , 107,	9.7	135
629	Src kinase activity is regulated by the SHP-1 protein-tyrosine phosphatase. <i>Journal of Biological Chemistry</i> , <b>1997</b> , 272, 21113-9	5.4	135
628	Epidermal growth factor receptor (EGFR) ubiquitination as a mechanism of acquired resistance escaping treatment by the anti-EGFR monoclonal antibody cetuximab. <i>Cancer Research</i> , <b>2007</b> , 67, 8240-7	10.1	135
627	Reexpression of the retinoblastoma protein in tumor cells induces senescence and telomerase inhibition. <i>Oncogene</i> , <b>1997</b> , 15, 2589-96	9.2	134
626	A Pan-Cancer Analysis of Enhancer Expression in Nearly 9000 Patient Samples. <i>Cell</i> , <b>2018</b> , 173, 386-399.e12	14.2	133
625	Mammalian target of rapamycin activator RHEB is frequently overexpressed in human carcinomas and is critical and sufficient for skin epithelial carcinogenesis. <i>Cancer Research</i> , <b>2010</b> , 70, 3287-98	10.1	133

624	HDAC4-regulated STAT1 activation mediates platinum resistance in ovarian cancer. <i>Cancer Research</i> , <b>2011</b> , 71, 4412-22	10.1	132
623	Dose-dependent induction of distinct phenotypic responses to Notch pathway activation in mammary epithelial cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2010</b> , 107, 5012-7	11.5	129
622	CXCR2 promotes ovarian cancer growth through dysregulated cell cycle, diminished apoptosis, and enhanced angiogenesis. <i>Clinical Cancer Research</i> , <b>2010</b> , 16, 3875-86	12.9	127
621	Regulation of glutamine carrier proteins by RNF5 determines breast cancer response to ER stress-inducing chemotherapies. <i>Cancer Cell</i> , <b>2015</b> , 27, 354-69	24.3	126
620	Inhibition of mTORC1/2 overcomes resistance to MAPK pathway inhibitors mediated by PGC1 $\alpha$ and oxidative phosphorylation in melanoma. <i>Cancer Research</i> , <b>2014</b> , 74, 7037-47	10.1	126
619	Elevated levels and altered fatty acid composition of plasma lysophosphatidylcholine(lysoPC) in ovarian cancer patients. <i>International Journal of Cancer</i> , <b>1997</b> , 71, 31-4	7.5	126
618	Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer. <i>Annals of Oncology</i> , <b>2017</b> , 28, 512-518	10.3	125
617	Characterization of twenty-five ovarian tumour cell lines that phenocopy primary tumours. <i>Nature Communications</i> , <b>2015</b> , 6, 7419	17.4	125
616	A kinome-wide screen identifies the insulin/IGF-I receptor pathway as a mechanism of escape from hormone dependence in breast cancer. <i>Cancer Research</i> , <b>2011</b> , 71, 6773-84	10.1	125
615	Beta-arrestin/Ral signaling regulates lysophosphatidic acid-mediated migration and invasion of human breast tumor cells. <i>Molecular Cancer Research</i> , <b>2009</b> , 7, 1064-77	6.6	125
614	Carba analogs of cyclic phosphatidic acid are selective inhibitors of autotaxin and cancer cell invasion and metastasis. <i>Journal of Biological Chemistry</i> , <b>2006</b> , 281, 22786-93	5.4	125
613	SHP-1 regulates Lck-induced phosphatidylinositol 3-kinase phosphorylation and activity. <i>Journal of Biological Chemistry</i> , <b>1999</b> , 274, 27583-9	5.4	125
612	Clinical significance of CTNNB1 mutation and Wnt pathway activation in endometrioid endometrial carcinoma. <i>Journal of the National Cancer Institute</i> , <b>2014</b> , 106,	9.7	124
611	Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRO. <i>Journal of the National Cancer Institute</i> , <b>2002</b> , 94, 844-51	9.7	124
610	Fas (CD95) participates in peripheral T cell deletion and associated apoptosis in vivo. <i>International Immunology</i> , <b>1995</b> , 7, 1451-8	4.9	124
609	BRIT1 regulates early DNA damage response, chromosomal integrity, and cancer. <i>Cancer Cell</i> , <b>2006</b> , 10, 145-57	24.3	123
608	Phosphorylation of TNF-alpha converting enzyme by gastrin-releasing peptide induces amphiregulin release and EGF receptor activation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2006</b> , 103, 6901-6	11.5	122
607	Systematic Analysis of Splice-Site-Creating Mutations in Cancer. <i>Cell Reports</i> , <b>2018</b> , 23, 270-281.e3	10.6	121

606	Cancer Systems Biology: a peek into the future of patient care?. <i>Nature Reviews Clinical Oncology</i> , <b>2014</b> , 11, 167-76	19.4	120
605	Biomarkers of response to Akt inhibitor MK-2206 in breast cancer. <i>Clinical Cancer Research</i> , <b>2012</b> , 18, 5816-28	12.9	120
604	Olaparib and E-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial. <i>Lancet Oncology, The</i> , <b>2019</b> , 20, 570-580	21.7	118
603	Autotaxin expression from synovial fibroblasts is essential for the pathogenesis of modeled arthritis. <i>Journal of Experimental Medicine</i> , <b>2012</b> , 209, 925-33	16.6	118
602	Realizing the promise of reverse phase protein arrays for clinical, translational, and basic research: a workshop report: the RPPA (Reverse Phase Protein Array) society. <i>Molecular and Cellular Proteomics</i> , <b>2014</b> , 13, 1625-43	7.6	117
601	CTNNB1 (beta-catenin) mutation identifies low grade, early stage endometrial cancer patients at increased risk of recurrence. <i>Modern Pathology</i> , <b>2017</b> , 30, 1032-1041	9.8	116
600	Clinical and genomic landscape of gastric cancer with a mesenchymal phenotype. <i>Nature Communications</i> , <b>2018</b> , 9, 1777	17.4	116
599	Recombinant human erythropoietin antagonizes trastuzumab treatment of breast cancer cells via Jak2-mediated Src activation and PTEN inactivation. <i>Cancer Cell</i> , <b>2010</b> , 18, 423-35	24.3	116
598	Microtubulin acetylation elevated in metastatic and basal-like breast cancer cells promotes microtentacle formation, adhesion, and invasive migration. <i>Cancer Research</i> , <b>2015</b> , 75, 203-15	10.1	114
597	Systematic Functional Annotation of Somatic Mutations in Cancer. <i>Cancer Cell</i> , <b>2018</b> , 33, 450-462.e10	24.3	114
596	A Unified Approach to Targeting the Lysosome's Degradative and Growth Signaling Roles. <i>Cancer Discovery</i> , <b>2017</b> , 7, 1266-1283	24.4	114
595	Autotaxin/lysopholipase D and lysophosphatidic acid regulate murine hemostasis and thrombosis. <i>Journal of Biological Chemistry</i> , <b>2009</b> , 284, 7385-94	5.4	113
594	Clinical assessment of PTEN loss in endometrial carcinoma: immunohistochemistry outperforms gene sequencing. <i>Modern Pathology</i> , <b>2012</b> , 25, 699-708	9.8	113
593	G-CSF induced reactive oxygen species involves Lyn-PI3-kinase-Akt and contributes to myeloid cell growth. <i>Blood</i> , <b>2006</b> , 107, 1847-56	2.2	113
592	Cancer Cells Co-opt the Neuronal Redox-Sensing Channel TRPA1 to Promote Oxidative-Stress Tolerance. <i>Cancer Cell</i> , <b>2018</b> , 33, 985-1003.e7	24.3	113
591	Molecular Characterization and Clinical Relevance of Metabolic Expression Subtypes in Human Cancers. <i>Cell Reports</i> , <b>2018</b> , 23, 255-269.e4	10.6	112
590	The RAC1 P29S hotspot mutation in melanoma confers resistance to pharmacological inhibition of RAF. <i>Cancer Research</i> , <b>2014</b> , 74, 4845-4852	10.1	111
589	Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in mutant cancers. <i>Science Translational Medicine</i> , <b>2017</b> , 9,	17.5	109

588	Integrative analysis of cyclin protein levels identifies cyclin b1 as a classifier and predictor of outcomes in breast cancer. <i>Clinical Cancer Research</i> , <b>2009</b> , 15, 3654-62	12.9	109
587	Monitoring autophagy in glioblastoma with antibody against isoform B of human microtubule-associated protein 1 light chain 3. <i>Autophagy</i> , <b>2008</b> , 4, 467-75	10.2	109
586	Pharmacodynamic markers of perifosine efficacy. <i>Clinical Cancer Research</i> , <b>2007</b> , 13, 7421-31	12.9	107
585	In silico prediction of physical protein interactions and characterization of interactome orphans. <i>Nature Methods</i> , <b>2015</b> , 12, 79-84	21.6	106
584	3-Phosphoinositide-dependent kinase 1 potentiates upstream lesions on the phosphatidylinositol 3-kinase pathway in breast carcinoma. <i>Cancer Research</i> , <b>2009</b> , 69, 6299-306	10.1	106
583	Acquired resistance to erlotinib in A-431 epidermoid cancer cells requires down-regulation of MMAC1/PTEN and up-regulation of phosphorylated Akt. <i>Cancer Research</i> , <b>2007</b> , 67, 5779-88	10.1	102
582	Amplification of MDS1/EVI1 and EVI1, located in the 3q26.2 amplicon, is associated with favorable patient prognosis in ovarian cancer. <i>Cancer Research</i> , <b>2007</b> , 67, 3074-84	10.1	102
581	Systematic characterization of A-to-I RNA editing hotspots in microRNAs across human cancers. <i>Genome Research</i> , <b>2017</b> , 27, 1112-1125	9.7	100
580	PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas. <i>Nature</i> , <b>2017</b> , 550, 133-136	50.4	100
579	BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation. <i>Molecular Oncology</i> , <b>2013</b> , 7, 567-79	7.9	100
578	The human lipid phosphate phosphatase-3 decreases the growth, survival, and tumorigenesis of ovarian cancer cells: validation of the lysophosphatidic acid signaling cascade as a target for therapy in ovarian cancer. <i>Cancer Research</i> , <b>2003</b> , 63, 1073-82	10.1	100
577	Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma. <i>Journal of Investigative Dermatology</i> , <b>2015</b> , 135, 508-515	4.3	99
576	Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations. <i>Cancer Research</i> , <b>2015</b> , 75, 5341-54	10.1	99
575	Perturbation biology: inferring signaling networks in cellular systems. <i>PLoS Computational Biology</i> , <b>2013</b> , 9, e1003290	5	98
574	Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models. <i>Scientific Reports</i> , <b>2019</b> , 9, 1853	4.9	98
573	DNA-PK mediates AKT activation and apoptosis inhibition in clinically acquired platinum resistance. <i>Neoplasia</i> , <b>2011</b> , 13, 1069-80	6.4	97
572	Overcoming implementation challenges of personalized cancer therapy. <i>Nature Reviews Clinical Oncology</i> , <b>2012</b> , 9, 542-8	19.4	96
571	Sequential Therapy with PARP and WEE1 Inhibitors Minimizes Toxicity while Maintaining Efficacy. <i>Cancer Cell</i> , <b>2019</b> , 35, 851-867.e7	24.3	94

570	AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies. <i>Molecular Cancer Therapeutics</i> , <b>2016</b> , 15, 2563-2574	6.1	94
569	Cross-species hybridization of microarrays for studying tumor transcriptome of brain metastasis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2011</b> , 108, 17456-61	11.5	94
568	Aurora kinase A promotes ovarian tumorigenesis through dysregulation of the cell cycle and suppression of BRCA2. <i>Clinical Cancer Research</i> , <b>2010</b> , 16, 3171-81	12.9	92
567	Role of glycogen synthase kinase 3beta in rapamycin-mediated cell cycle regulation and chemosensitivity. <i>Cancer Research</i> , <b>2005</b> , 65, 1961-72	10.1	92
566	A-to-I RNA Editing Contributes to Proteomic Diversity in Cancer. <i>Cancer Cell</i> , <b>2018</b> , 33, 817-828.e7	24.3	91
565	Personalized Preclinical Trials in BRAF Inhibitor-Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 1592-602	12.9	91
564	Identification of a phosphothionate analogue of lysophosphatidic acid (LPA) as a selective agonist of the LPA3 receptor. <i>Journal of Biological Chemistry</i> , <b>2003</b> , 278, 11962-9	5.4	90
563	Defective cytochrome c-dependent caspase activation in ovarian cancer cell lines due to diminished or absent apoptotic protease activating factor-1 activity. <i>Journal of Biological Chemistry</i> , <b>2001</b> , 276, 34244-51	5.4	90
562	A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma. <i>Cell Reports</i> , <b>2017</b> , 21, 1953-1967	10.6	89
561	Targeting the epidermal growth factor receptor in epithelial ovarian cancer: current knowledge and future challenges. <i>Journal of Oncology</i> , <b>2010</b> , 2010, 568938	4.5	89
560	Simultaneous inhibition of PDK1/AKT and Fms-like tyrosine kinase 3 signaling by a small-molecule KP372-1 induces mitochondrial dysfunction and apoptosis in acute myelogenous leukemia. <i>Cancer Research</i> , <b>2006</b> , 66, 3737-46	10.1	89
559	ARHI is a Ras-related small G-protein with a novel N-terminal extension that inhibits growth of ovarian and breast cancers. <i>Oncogene</i> , <b>2003</b> , 22, 2897-909	9.2	89
558	Autophagy: a novel mechanism of synergistic cytotoxicity between doxorubicin and roscovitine in a sarcoma model. <i>Cancer Research</i> , <b>2008</b> , 68, 7966-74	10.1	88
557	cMET and phospho-cMET protein levels in breast cancers and survival outcomes. <i>Clinical Cancer Research</i> , <b>2012</b> , 18, 2269-77	12.9	86
556	The Genomic Landscape and Pharmacogenomic Interactions of Clock Genes in Cancer Chronotherapy. <i>Cell Systems</i> , <b>2018</b> , 6, 314-328.e2	10.6	85
555	Concordance of genomic alterations between primary and recurrent breast cancer. <i>Molecular Cancer Therapeutics</i> , <b>2014</b> , 13, 1382-9	6.1	85
554	Building a personalized medicine infrastructure at a major cancer center. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 1849-57	2.2	85
553	Two phases of mitogenic signaling unveil roles for p53 and EGR1 in elimination of inconsistent growth signals. <i>Molecular Cell</i> , <b>2011</b> , 42, 524-35	17.6	85



552	Assessing BRCA carrier probabilities in extended families. <i>Journal of Clinical Oncology</i> , <b>2006</b> , 24, 354-60	2.2	85
551	Verteporfin inhibits YAP function through up-regulating 14-3-3 $\beta$ sequestering YAP in the cytoplasm. <i>American Journal of Cancer Research</i> , <b>2016</b> , 6, 27-37	4.4	85
550	A Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF- $\beta$ Superfamily. <i>Cell Systems</i> , <b>2018</b> , 7, 422-437.e7	10.6	85
549	Breast cancer quantitative proteome and proteogenomic landscape. <i>Nature Communications</i> , <b>2019</b> , 10, 1600	17.4	84
548	ATX-LPA receptor axis in inflammation and cancer. <i>Cell Cycle</i> , <b>2009</b> , 8, 3695-701	4.7	84
547	Reciprocal regulation of c-Src and STAT3 in non-small cell lung cancer. <i>Clinical Cancer Research</i> , <b>2009</b> , 15, 6852-61	12.9	84
546	Mitogens trigger a calcium-independent signal for proliferation in phorbol-ester-treated lymphocytes. <i>Nature</i> , <b>1985</b> , 315, 419-20	50.4	84
545	Mesenchymal gene program-expressing ovarian cancer spheroids exhibit enhanced mesothelial clearance. <i>Journal of Clinical Investigation</i> , <b>2014</b> , 124, 2611-25	15.9	84
544	Co-clinical assessment identifies patterns of BRAF inhibitor resistance in melanoma. <i>Journal of Clinical Investigation</i> , <b>2015</b> , 125, 1459-70	15.9	84
543	Gene expression signature analysis identifies vorinostat as a candidate therapy for gastric cancer. <i>PLoS ONE</i> , <b>2011</b> , 6, e24662	3.7	83
542	Targeting integrin-linked kinase inhibits Akt signaling pathways and decreases tumor progression of human glioblastoma. <i>Molecular Cancer Therapeutics</i> , <b>2005</b> , 4, 1681-8	6.1	82
541	Characterization of the role for calcium influx in mitogen-induced triggering of human T cells. Identification of calcium-dependent and calcium-independent signals. <i>European Journal of Immunology</i> , <b>1986</b> , 16, 907-12	6.1	81
540	Dual targeting of AKT and mammalian target of rapamycin: a potential therapeutic approach for malignant peripheral nerve sheath tumor. <i>Molecular Cancer Therapeutics</i> , <b>2009</b> , 8, 1157-68	6.1	80
539	Liquid chromatography mass spectrometry for quantifying plasma lysophospholipids: potential biomarkers for cancer diagnosis. <i>Methods in Enzymology</i> , <b>2007</b> , 433, 1-25	1.7	80
538	Yes-associated protein 1 and transcriptional coactivator with PDZ-binding motif activate the mammalian target of rapamycin complex 1 pathway by regulating amino acid transporters in hepatocellular carcinoma. <i>Hepatology</i> , <b>2016</b> , 63, 159-72	11.2	80
537	Functional proteomics can define prognosis and predict pathologic complete response in patients with breast cancer. <i>Clinical Proteomics</i> , <b>2011</b> , 8, 11	5	79
536	Inhibition of Akt survival pathway by a small-molecule inhibitor in human glioblastoma. <i>Molecular Cancer Therapeutics</i> , <b>2006</b> , 5, 637-44	6.1	79
535	Cupid: simultaneous reconstruction of microRNA-target and ceRNA networks. <i>Genome Research</i> , <b>2015</b> , 25, 257-67	9.7	78

534	Lactate dehydrogenase B: a metabolic marker of response to neoadjuvant chemotherapy in breast cancer. <i>Clinical Cancer Research</i> , <b>2013</b> , 19, 3703-13	12.9	78
533	Interaction of the Wiskott-Aldrich syndrome protein with sorting nexin 9 is required for CD28 endocytosis and cosignaling in T cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2007</b> , 104, 1593-8	11.5	78
532	Inhibition of the phosphatidylinositol-3 kinase/Akt promotes G1 cell cycle arrest and apoptosis in Hodgkin lymphoma. <i>British Journal of Haematology</i> , <b>2006</b> , 132, 503-11	4.5	78
531	Immuno-genomic landscape of osteosarcoma. <i>Nature Communications</i> , <b>2020</b> , 11, 1008	17.4	77
530	Lysophosphatidic acid production and action: validated targets in cancer?. <i>Journal of Cellular Biochemistry</i> , <b>2004</b> , 92, 1115-40	4.7	77
529	Evidence of haplotype insufficiency in human cells containing a germline mutation in BRCA1 or BRCA2. <i>International Journal of Cancer</i> , <b>2002</b> , 97, 557-61	7.5	77
528	Characterization of Hypoxia-associated Molecular Features to Aid Hypoxia-Targeted Therapy. <i>Nature Metabolism</i> , <b>2019</b> , 1, 431-444	14.6	76
527	Clinical actionability enhanced through deep targeted sequencing of solid tumors. <i>Clinical Chemistry</i> , <b>2015</b> , 61, 544-53	5.5	76
526	Validation of reverse phase protein array for practical screening of potential biomarkers in serum and plasma: accurate detection of CA19-9 levels in pancreatic cancer. <i>Proteomics</i> , <b>2008</b> , 8, 3051-60	4.8	76
525	A retrovirus-based protein complementation assay screen reveals functional AKT1-binding partners. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2006</b> , 103, 15014-9	11.5	76
524	Integrin-linked kinase is a potential therapeutic target for anaplastic thyroid cancer. <i>Molecular Cancer Therapeutics</i> , <b>2005</b> , 4, 1146-56	6.1	76
523	Effect of lysophospholipids on signaling in the human Jurkat T cell line. <i>Journal of Cellular Physiology</i> , <b>1995</b> , 163, 441-50	7	76
522	CanDrA: cancer-specific driver missense mutation annotation with optimized features. <i>PLoS ONE</i> , <b>2013</b> , 8, e77945	3.7	76
521	Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation. <i>Breast Cancer Research</i> , <b>2019</b> , 21, 78	8.3	75
520	Multiplatform-based molecular subtypes of non-small-cell lung cancer. <i>Oncogene</i> , <b>2017</b> , 36, 1384-1393	9.2	75
519	A gene expression signature from human breast cancer cells with acquired hormone independence identifies MYC as a mediator of antiestrogen resistance. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 2024-34	12.9	75
518	Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome Consortium. <i>Annals of Oncology</i> , <b>2019</b> , 30, 597-603	10.3	74
517	Integrative analysis of proteomic signatures, mutations, and drug responsiveness in the NCI 60 cancer cell line set. <i>Molecular Cancer Therapeutics</i> , <b>2010</b> , 9, 257-67	6.1	74

516	Reverse-phase protein array profiling of oropharyngeal cancer and significance of PIK3CA mutations in HPV-associated head and neck cancer. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 2300-11	12.9	73
515	Rab GTPases implicated in inherited and acquired disorders. <i>Seminars in Cell and Developmental Biology</i> , <b>2011</b> , 22, 57-68	7.5	73
514	Transcriptional landscape and clinical utility of enhancer RNAs for eRNA-targeted therapy in cancer. <i>Nature Communications</i> , <b>2019</b> , 10, 4562	17.4	72
513	Lysophosphatidic acid is a major regulator of growth-regulated oncogene alpha in ovarian cancer. <i>Cancer Research</i> , <b>2006</b> , 66, 2740-8	10.1	72
512	The role of genetic abnormalities of PTEN and the phosphatidylinositol 3-kinase pathway in breast and ovarian tumorigenesis, prognosis, and therapy. <i>Seminars in Oncology</i> , <b>2001</b> , 28, 125-141	5.5	72
511	Myristoylation confers noncanonical AMPK functions in autophagy selectivity and mitochondrial surveillance. <i>Nature Communications</i> , <b>2015</b> , 6, 7926	17.4	71
510	Comprehensive characterization of circular RNAs in ~ 1000 human cancer cell lines. <i>Genome Medicine</i> , <b>2019</b> , 11, 55	14.4	70
509	EGR1 and the ERK-ERF axis drive mammary cell migration in response to EGF. <i>FASEB Journal</i> , <b>2012</b> , 26, 1582-92	0.9	70
508	Targeting the phosphatidylinositol 3-kinase/Akt pathway for enhancing breast cancer cells to radiotherapy. <i>Molecular Cancer Therapeutics</i> , <b>2003</b> , 2, 353-60	6.1	70
507	Antitumor mechanisms of combined gastrin-releasing peptide receptor and epidermal growth factor receptor targeting in head and neck cancer. <i>Molecular Cancer Therapeutics</i> , <b>2007</b> , 6, 1414-24	6.1	69
506	Structure-activity relationships of fluorinated lysophosphatidic acid analogues. <i>Journal of Medicinal Chemistry</i> , <b>2005</b> , 48, 3319-27	8.3	69
505	Src promotes estrogen-dependent estrogen receptor alpha proteolysis in human breast cancer. <i>Journal of Clinical Investigation</i> , <b>2007</b> , 117, 2205-15	15.9	69
504	The emerging role of the RAB25 small GTPase in cancer. <i>Traffic</i> , <b>2009</b> , 10, 1561-8	5.7	68
503	High stearoyl-CoA desaturase 1 expression is associated with shorter survival in breast cancer patients. <i>Breast Cancer Research and Treatment</i> , <b>2013</b> , 137, 319-27	4.4	67
502	Establishment of Patient-Derived Tumor Xenograft Models of Epithelial Ovarian Cancer for Preclinical Evaluation of Novel Therapeutics. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 1263-1273	12.9	67
501	Downregulation of SMG-1 in HPV-positive head and neck squamous cell carcinoma due to promoter hypermethylation correlates with improved survival. <i>Clinical Cancer Research</i> , <b>2012</b> , 18, 1257-67	12.9	67
500	Expression of p16 induces transcriptional downregulation of the RB gene. <i>Oncogene</i> , <b>1998</b> , 16, 1-8	9.2	67
499	Uptake of extracellular Ca <sup>2+</sup> and not recruitment from internal stores is essential for T lymphocyte proliferation. <i>European Journal of Immunology</i> , <b>1988</b> , 18, 917-22	6.1	67

498	Machine Learning Detects Pan-cancer Ras Pathway Activation in The Cancer Genome Atlas. <i>Cell Reports</i> , <b>2018</b> , 23, 172-180.e3	10.6	66
497	mTOR Inhibitors Suppress Homologous Recombination Repair and Synergize with PARP Inhibitors via Regulating SUV39H1 in BRCA-Proficient Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 1699-712	12.9	65
496	Transcriptional activation of the proglucagon gene by lithium and beta-catenin in intestinal endocrine L cells. <i>Journal of Biological Chemistry</i> , <b>2003</b> , 278, 1380-7	5.4	65
495	Integrated Patient-Derived Models Delineate Individualized Therapeutic Vulnerabilities of Pancreatic Cancer. <i>Cell Reports</i> , <b>2016</b> , 16, 2017-31	10.6	65
494	Role of decreased levels of lipid phosphate phosphatase-1 in accumulation of lysophosphatidic acid in ovarian cancer. <i>Clinical Cancer Research</i> , <b>2003</b> , 9, 3534-45	12.9	65
493	Tat-activating regulatory DNA-binding protein regulates glycolysis in hepatocellular carcinoma by regulating the platelet isoform of phosphofructokinase through microRNA 520. <i>Hepatology</i> , <b>2013</b> , 58, 182-91	11.2	64
492	Lysophosphatidylcholine stimulates activator protein 1 and the c-Jun N-terminal kinase activity. <i>Journal of Biological Chemistry</i> , <b>1997</b> , 272, 13683-9	5.4	63
491	Mechanisms underlying p53 regulation of PIK3CA transcription in ovarian surface epithelium and in ovarian cancer. <i>Journal of Cell Science</i> , <b>2008</b> , 121, 664-74	5.3	63
490	A comprehensive evaluation of biomarkers predictive of response to PI3K inhibitors and of resistance mechanisms in head and neck squamous cell carcinoma. <i>Molecular Cancer Therapeutics</i> , <b>2014</b> , 13, 2738-50	6.1	62
489	Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer. <i>Gynecologic Oncology</i> , <b>2012</b> , 126, 47-53	4.9	62
488	Rab25 increases cellular ATP and glycogen stores protecting cancer cells from bioenergetic stress. <i>EMBO Molecular Medicine</i> , <b>2012</b> , 4, 125-41	12	62
487	Frequent mutation of receptor protein tyrosine phosphatases provides a mechanism for STAT3 hyperactivation in head and neck cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2014</b> , 111, 1114-9	11.5	62
486	Network analysis of the focal adhesion to invadopodia transition identifies a PI3K-PKC $\epsilon$ invasive signaling axis. <i>Science Signaling</i> , <b>2012</b> , 5, ra66	8.8	62
485	BRAF Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics System. <i>Molecular Cancer Therapeutics</i> , <b>2016</b> , 15, 1397-404	6.1	61
484	Naturally occurring neomorphic PIK3R1 mutations activate the MAPK pathway, dictating therapeutic response to MAPK pathway inhibitors. <i>Cancer Cell</i> , <b>2014</b> , 26, 479-94	24.3	61
483	Tumor epidermal growth factor receptor and EGFR PY1068 are independent prognostic indicators for head and neck squamous cell carcinoma. <i>Clinical Cancer Research</i> , <b>2012</b> , 18, 2278-89	12.9	61
482	Phosphorylated 4E-BP1 is associated with poor survival in melanoma. <i>Clinical Cancer Research</i> , <b>2009</b> , 15, 2872-8	12.9	61
481	Mechanistic basis for overcoming platinum resistance using copper chelating agents. <i>Molecular Cancer Therapeutics</i> , <b>2012</b> , 11, 2483-94	6.1	61

480	Growth signal transduction by the human interleukin-2 receptor requires cytoplasmic tyrosines of the beta chain and non-tyrosine residues of the gamma c chain. <i>Journal of Biological Chemistry</i> , <b>1995</b> , 270, 21729-37	5.4	61
479	Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models. <i>Nature Communications</i> , <b>2020</b> , 11, 3726	17.4	61
478	Functional variomics and network perturbation: connecting genotype to phenotype in cancer. <i>Nature Reviews Genetics</i> , <b>2017</b> , 18, 395-410	30.1	60
477	Future for ovarian cancer screening: novel markers from emerging technologies of transcriptional profiling and proteomics. <i>Journal of the National Cancer Institute</i> , <b>2001</b> , 93, 1437-9	9.7	60
476	Akt and ERK control the proliferative response of mammary epithelial cells to the growth factors IGF-1 and EGF through the cell cycle inhibitor p57Kip2. <i>Science Signaling</i> , <b>2012</b> , 5, ra19	8.8	59
475	Overexpression of kallikrein 10 in epithelial ovarian carcinomas. <i>Gynecologic Oncology</i> , <b>2003</b> , 90, 44-50	4.9	59
474	Functional LCK Is required for optimal CD28-mediated activation of the TEC family tyrosine kinase EMT/ITK. <i>Journal of Biological Chemistry</i> , <b>1996</b> , 271, 7079-83	5.4	59
473	Comprehensive Characterization of Alternative Polyadenylation in Human Cancer. <i>Journal of the National Cancer Institute</i> , <b>2018</b> , 110, 379-389	9.7	58
472	Mask is required for the activity of the Hippo pathway effector Yki/YAP. <i>Current Biology</i> , <b>2013</b> , 23, 229-35.	35.3	58
471	Proteomic patterns in serum and identification of ovarian cancer. <i>Lancet, The</i> , <b>2002</b> , 360, 170-171	4.0	58
470	Transforming growth factor-beta inhibits proliferation of human ovarian cancer cells obtained from ascites. <i>Cancer</i> , <b>1994</b> , 74, 93-9	6.4	58
469	Integrative clustering reveals a novel split in the luminal A subtype of breast cancer with impact on outcome. <i>Breast Cancer Research</i> , <b>2017</b> , 19, 44	8.3	57
468	Multi-omics analysis reveals neoantigen-independent immune cell infiltration in copy-number driven cancers. <i>Nature Communications</i> , <b>2018</b> , 9, 1317	17.4	57
467	Influence of DNA copy number and mRNA levels on the expression of breast cancer related proteins. <i>Molecular Oncology</i> , <b>2013</b> , 7, 704-18	7.9	57
466	Knockdown of p53 combined with expression of the catalytic subunit of telomerase is sufficient to immortalize primary human ovarian surface epithelial cells. <i>Carcinogenesis</i> , <b>2007</b> , 28, 174-82	4.6	57
465	Sex-associated molecular differences for cancer immunotherapy. <i>Nature Communications</i> , <b>2020</b> , 11, 1779	17.4	57
464	Integrated Genomic Analysis of the Ubiquitin Pathway across Cancer Types. <i>Cell Reports</i> , <b>2018</b> , 23, 213-226.	26.3	56
463	Combined Src and aromatase inhibition impairs human breast cancer growth in vivo and bypass pathways are activated in AZD0530-resistant tumors. <i>Clinical Cancer Research</i> , <b>2009</b> , 15, 3396-405	12.9	56

462	Direct Upregulation of STAT3 by MicroRNA-551b-3p Deregulates Growth and Metastasis of Ovarian Cancer. <i>Cell Reports</i> , <b>2016</b> , 15, 1493-1504	10.6	56
461	EGFR-Phosphorylated Platelet Isoform of Phosphofructokinase 1 Promotes PI3K Activation. <i>Molecular Cell</i> , <b>2018</b> , 70, 197-210.e7	17.6	55
460	Loss of progesterone receptor links to high proliferation and increases from primary to metastatic endometrial cancer lesions. <i>European Journal of Cancer</i> , <b>2014</b> , 50, 3003-10	7.5	55
459	RET fusion as a novel driver of medullary thyroid carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2015</b> , 100, 788-93	5.6	55
458	Telomere 3' overhang-specific DNA oligonucleotides induce autophagy in malignant glioma cells. <i>FASEB Journal</i> , <b>2007</b> , 21, 2918-30	0.9	55
457	Osmotic activation of the Na <sup>+</sup> /H <sup>+</sup> antiport in protein kinase C-depleted lymphocytes. <i>Biochemical and Biophysical Research Communications</i> , <b>1986</b> , 134, 8-13	3.4	55
456	PTK6 regulates IGF-1-induced anchorage-independent survival. <i>PLoS ONE</i> , <b>2010</b> , 5, e11729	3.7	55
455	Mouse models of human PIK3CA-related brain overgrowth have acutely treatable epilepsy. <i>ELife</i> , <b>2015</b> , 4,	8.9	55
454	Nicotinic acetylcholine receptor region on chromosome 15q25 and lung cancer risk among African Americans: a case-control study. <i>Journal of the National Cancer Institute</i> , <b>2010</b> , 102, 1199-205	9.7	54
453	Enantioselective responses to a phosphorothioate analogue of lysophosphatidic acid with LPA3 receptor-selective agonist activity. <i>Journal of Medicinal Chemistry</i> , <b>2003</b> , 46, 5575-8	8.3	54
452	RNA editing derived epitopes function as cancer antigens to elicit immune responses. <i>Nature Communications</i> , <b>2018</b> , 9, 3919	17.4	54
451	Genetic events that limit the efficacy of MEK and RTK inhibitor therapies in a mouse model of KRAS-driven pancreatic cancer. <i>Cancer Research</i> , <b>2015</b> , 75, 1091-101	10.1	53
450	Integrative epidemiology: from risk assessment to outcome prediction. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 267-75	2.2	53
449	Functional proteomic analysis of advanced serous ovarian cancer using reverse phase protein array: TGF-beta pathway signaling indicates response to primary chemotherapy. <i>Clinical Cancer Research</i> , <b>2010</b> , 16, 2852-60	12.9	52
448	Rapamycin regulates stearyl CoA desaturase 1 expression in breast cancer. <i>Molecular Cancer Therapeutics</i> , <b>2010</b> , 9, 2770-84	6.1	52
447	Intratumoral epidermal growth factor receptor antisense DNA therapy in head and neck cancer: first human application and potential antitumor mechanisms. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 1235-42	2.2	52
446	Motif analysis of the tumor suppressor gene MMAC/PTEN identifies tyrosines critical for tumor suppression and lipid phosphatase activity. <i>Oncogene</i> , <b>2002</b> , 21, 2357-64	9.2	52
445	Phosphorylation of ETS1 by Src family kinases prevents its recognition by the COP1 tumor suppressor. <i>Cancer Cell</i> , <b>2014</b> , 26, 222-34	24.3	51

444	Phosphatase PTP4A3 Promotes Triple-Negative Breast Cancer Growth and Predicts Poor Patient Survival. <i>Cancer Research</i> , <b>2016</b> , 76, 1942-53	10.1	51
443	Explore, Visualize, and Analyze Functional Cancer Proteomic Data Using the Cancer Proteome Atlas. <i>Cancer Research</i> , <b>2017</b> , 77, e51-e54	10.1	50
442	PIK3CA variants selectively initiate brain hyperactivity during gliomagenesis. <i>Nature</i> , <b>2020</b> , 578, 166-171	50.4	50
441	Gene expression, molecular class changes, and pathway analysis after neoadjuvant systemic therapy for breast cancer. <i>Clinical Cancer Research</i> , <b>2012</b> , 18, 1109-19	12.9	50
440	Rab25 in cancer: a brief update. <i>Biochemical Society Transactions</i> , <b>2012</b> , 40, 1404-8	5.1	50
439	AKT-dependent phosphorylation of Niban regulates nucleophosmin- and MDM2-mediated p53 stability and cell apoptosis. <i>EMBO Reports</i> , <b>2012</b> , 13, 554-60	6.5	50
438	Proteomic profiling identifies pathways dysregulated in non-small cell lung cancer and an inverse association of AMPK and adhesion pathways with recurrence. <i>Journal of Thoracic Oncology</i> , <b>2010</b> , 5, 1894-904	8.9	50
437	Paclitaxel induces inactivation of p70 S6 kinase and phosphorylation of Thr421 and Ser424 via multiple signaling pathways in mitosis. <i>Oncogene</i> , <b>2003</b> , 22, 484-97	9.2	50
436	Cellular origins and targets of costimulator (IL2). <i>Immunological Reviews</i> , <b>1980</b> , 51, 157-75	11.3	50
435	Cyclin E Associates with the Lipogenic Enzyme ATP-Citrate Lyase to Enable Malignant Growth of Breast Cancer Cells. <i>Cancer Research</i> , <b>2016</b> , 76, 2406-18	10.1	50
434	Benzyl and naphthalene methylphosphonic acid inhibitors of autotaxin with anti-invasive and anti-metastatic activity. <i>ChemMedChem</i> , <b>2011</b> , 6, 922-35	3.7	49
433	Steroid receptor coactivator-3 expression in lung cancer and its role in the regulation of cancer cell survival and proliferation. <i>Cancer Research</i> , <b>2010</b> , 70, 6477-85	10.1	49
432	Src Inhibition with saracatinib reverses fulvestrant resistance in ER-positive ovarian cancer models in vitro and in vivo. <i>Clinical Cancer Research</i> , <b>2012</b> , 18, 5911-23	12.9	49
431	AMP-activated protein kinase signaling results in cytoplasmic sequestration of p27. <i>Cancer Research</i> , <b>2008</b> , 68, 6496-506	10.1	49
430	Genes affecting the cell cycle, growth, maintenance, and drug sensitivity are preferentially regulated by anti-HER2 antibody through phosphatidylinositol 3-kinase-AKT signaling. <i>Journal of Biological Chemistry</i> , <b>2005</b> , 280, 2092-104	5.4	49
429	A patient-derived-xenograft platform to study BRCA-deficient ovarian cancers. <i>JCI Insight</i> , <b>2017</b> , 2, e89760	6.0	49
428	Definition of PKC- $\beta$ CDK6, and MET as therapeutic targets in triple-negative breast cancer. <i>Cancer Research</i> , <b>2014</b> , 74, 4822-35	10.1	48
427	Sarcomatoid Renal Cell Carcinoma Has a Distinct Molecular Pathogenesis, Driver Mutation Profile, and Transcriptional Landscape. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 6686-6696	12.9	48

426	An efficient procedure for protein extraction from formalin-fixed, paraffin-embedded tissues for reverse phase protein arrays. <i>Proteome Science</i> , <b>2012</b> , 10, 56	2.6	48
425	Autotaxin and its product lysophosphatidic acid suppress brown adipose differentiation and promote diet-induced obesity in mice. <i>Molecular Endocrinology</i> , <b>2012</b> , 26, 786-97		48
424	ZNF217 suppresses cell death associated with chemotherapy and telomere dysfunction. <i>Human Molecular Genetics</i> , <b>2005</b> , 14, 3219-25	5.6	48
423	Estrogen-related receptor gamma functions as a tumor suppressor in gastric cancer. <i>Nature Communications</i> , <b>2018</b> , 9, 1920	17.4	48
422	Functional annotation of rare gene aberration drivers of pancreatic cancer. <i>Nature Communications</i> , <b>2016</b> , 7, 10500	17.4	47
421	Metabolic clusters of breast cancer in relation to gene- and protein expression subtypes. <i>Cancer &amp; Metabolism</i> , <b>2016</b> , 4, 12	5.4	47
420	Roles of genetic variants in the PI3K and RAS/RAF pathways in susceptibility to endometrial cancer and clinical outcomes. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2012</b> , 138, 377-85	4.9	47
419	A genetic mouse model of invasive endometrial cancer driven by concurrent loss of Pten and Lkb1 is highly responsive to mTOR inhibition. <i>Cancer Research</i> , <b>2014</b> , 74, 15-23	10.1	47
418	Evidence that phosphatidylinositol 3-kinase- and mitogen-activated protein kinase kinase-4/c-Jun NH2-terminal kinase-dependent Pathways cooperate to maintain lung cancer cell survival. <i>Journal of Biological Chemistry</i> , <b>2003</b> , 278, 23630-8	5.4	47
417	Adenovirus-mediated p53 growth inhibition of ovarian cancer cells is independent of endogenous p53 status. <i>Gynecologic Oncology</i> , <b>1999</b> , 75, 261-6	4.9	47
416	Cell cycle progression out of G1 sensitizes primary-cultured nontransformed T cells to TCR-mediated apoptosis. <i>Cellular Immunology</i> , <b>1996</b> , 170, 260-73	4.4	47
415	A Multi-center Study on the Reproducibility of Drug-Response Assays in Mammalian Cell Lines. <i>Cell Systems</i> , <b>2019</b> , 9, 35-48.e5	10.6	46
414	Favorable modulation of benign breast tissue and serum risk biomarkers is associated with > 10 % weight loss in postmenopausal women. <i>Breast Cancer Research and Treatment</i> , <b>2013</b> , 142, 119-32	4.4	46
413	Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors. <i>Oncotarget</i> , <b>2014</b> , 5, 8544-57	3.3	46
412	Activation of YAP1 is associated with poor prognosis and response to taxanes in ovarian cancer. <i>Anticancer Research</i> , <b>2014</b> , 34, 811-817	2.3	46
411	Regulation of the PI3K pathway through a p85 $\beta$ monomer-homodimer equilibrium. <i>ELife</i> , <b>2015</b> , 4, e068668.9		46
410	A novel derivative of the natural agent deguelin for cancer chemoprevention and therapy. <i>Cancer Prevention Research</i> , <b>2008</b> , 1, 577-87	3.2	45
409	Soft tissue sarcoma cells are highly sensitive to AKT blockade: a role for p53-independent up-regulation of GADD45 alpha. <i>Cancer Research</i> , <b>2008</b> , 68, 2895-903	10.1	45



408	Of spiders and crabs: the emergence of lysophospholipids and their metabolic pathways as targets for therapy in cancer. <i>Clinical Cancer Research</i> , <b>2006</b> , 12, 6598-602	12.9	45
407	The right drugs at the right time for the right patient: the MD Anderson precision oncology decision support platform. <i>Drug Discovery Today</i> , <b>2015</b> , 20, 1433-8	8.8	44
406	BRD4 facilitates replication stress-induced DNA damage response. <i>Oncogene</i> , <b>2018</b> , 37, 3763-3777	9.2	44
405	Frequency of mesenchymal-epithelial transition factor gene (MET) and the catalytic subunit of phosphoinositide-3-kinase (PIK3CA) copy number elevation and correlation with outcome in patients with early stage breast cancer. <i>Cancer</i> , <b>2013</b> , 119, 7-15	6.4	43
404	Targeting of PYK2 Synergizes with EGFR Antagonists in Basal-like TNBC and Circumvents HER3-Associated Resistance via the NEDD4-NDRG1 Axis. <i>Cancer Research</i> , <b>2017</b> , 77, 86-99	10.1	43
403	A gonadotropin-releasing hormone-responsive phosphatase hydrolyses lysophosphatidic acid within the plasma membrane of ovarian cancer cells. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2000</b> , 85, 3370-5	5.6	43
402	Co-targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor-resistant melanoma. <i>EMBO Molecular Medicine</i> , <b>2018</b> , 10,	12	42
401	Predicting time to ovarian carcinoma recurrence using protein markers. <i>Journal of Clinical Investigation</i> , <b>2013</b> , 123, 3740-50	15.9	42
400	Molecular profiling of endometrial carcinoma precursor, primary and metastatic lesions suggests different targets for treatment in obese compared to non-obese patients. <i>Oncotarget</i> , <b>2015</b> , 6, 1327-39	3.3	42
399	Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma. <i>JAMA Oncology</i> , <b>2015</b> , 1, 238-44	13.4	41
398	Proteomic Characterization of Head and Neck Cancer Patient-Derived Xenografts. <i>Molecular Cancer Research</i> , <b>2016</b> , 14, 278-86	6.6	41
397	Influence of biospecimen variables on proteomic biomarkers in breast cancer. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 3870-83	12.9	41
396	Differential roles of phosphoinositide-dependent protein kinase-1 and akt1 expression and phosphorylation in breast cancer cell resistance to Paclitaxel, Doxorubicin, and gemcitabine. <i>Molecular Pharmacology</i> , <b>2006</b> , 70, 1045-52	4.3	41
395	Heregulin-induced apoptosis is mediated by down-regulation of Bcl-2 and activation of caspase-7 and is potentiated by impairment of protein kinase C alpha activity. <i>Oncogene</i> , <b>2001</b> , 20, 8258-69	9.2	41
394	PTEN loss is a context-dependent outcome determinant in obese and non-obese endometrioid endometrial cancer patients. <i>Molecular Oncology</i> , <b>2015</b> , 9, 1694-703	7.9	40
393	TransVar: a multilevel variant annotator for precision genomics. <i>Nature Methods</i> , <b>2015</b> , 12, 1002-3	21.6	40
392	ERK and p38 MAPK Activities Determine Sensitivity to PI3K/mTOR Inhibition via Regulation of MYC and YAP. <i>Cancer Research</i> , <b>2016</b> , 76, 7168-7180	10.1	40
391	Multi-nucleated cells use ROS to induce breast cancer chemo-resistance in vitro and in vivo. <i>Oncogene</i> , <b>2018</b> , 37, 4546-4561	9.2	40

390	Androgen regulation of 5 $\alpha$ -reductase isoenzymes in prostate cancer: implications for prostate cancer prevention. <i>PLoS ONE</i> , <b>2011</b> , 6, e28840	3.7	40
389	PTEN deficiency is fully penetrant for prostate adenocarcinoma in C57BL/6 mice via mTOR-dependent growth. <i>American Journal of Pathology</i> , <b>2009</b> , 174, 1869-79	5.8	40
388	Glycogen synthase kinase 3beta is a negative regulator of growth factor-induced activation of the c-Jun N-terminal kinase. <i>Journal of Biological Chemistry</i> , <b>2004</b> , 279, 51075-81	5.4	40
387	Somatic mutations of PIK3R1 promote gliomagenesis. <i>PLoS ONE</i> , <b>2012</b> , 7, e49466	3.7	40
386	Using reverse-phase protein arrays as pharmacodynamic assays for functional proteomics, biomarker discovery, and drug development in cancer. <i>Seminars in Oncology</i> , <b>2016</b> , 43, 476-83	5.5	40
385	Role of RPL39 in Metaplastic Breast Cancer. <i>Journal of the National Cancer Institute</i> , <b>2017</b> , 109,	9.7	39
384	Musashi RNA-binding protein 2 regulates estrogen receptor 1 function in breast cancer. <i>Oncogene</i> , <b>2017</b> , 36, 1745-1752	9.2	39
383	A Ras homologue member 1 directly inhibits signal transducers and activators of transcription 3 translocation and activity in human breast and ovarian cancer cells. <i>Cancer Research</i> , <b>2005</b> , 65, 6701-10	10.1	39
382	Ability to Generate Patient-Derived Breast Cancer Xenografts Is Enhanced in Chemoresistant Disease and Predicts Poor Patient Outcomes. <i>PLoS ONE</i> , <b>2015</b> , 10, e0136851	3.7	39
381	Distinct histone modifications denote early stress-induced drug tolerance in cancer. <i>Oncotarget</i> , <b>2018</b> , 9, 8206-8222	3.3	39
380	Multi-omics prediction of immune-related adverse events during checkpoint immunotherapy. <i>Nature Communications</i> , <b>2020</b> , 11, 4946	17.4	39
379	Development and Validation of an Ultradeep Next-Generation Sequencing Assay for Testing of Plasma Cell-Free DNA from Patients with Advanced Cancer. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 5648-5656	12.9	38
378	Algorithmic guided screening of drug combinations of arbitrary size for activity against cancer cells. <i>Molecular Cancer Therapeutics</i> , <b>2009</b> , 8, 521-32	6.1	38
377	An inherent role of integrin-linked kinase-estrogen receptor alpha interaction in cell migration. <i>Cancer Research</i> , <b>2006</b> , 66, 11030-8	10.1	38
376	Increase of serum interleukin 2 receptor level in thermally injured patients. <i>Clinical Immunology and Immunopathology</i> , <b>1989</b> , 51, 205-15		38
375	Clinical next generation sequencing to identify actionable aberrations in a phase I program. <i>Oncotarget</i> , <b>2015</b> , 6, 20099-110	3.3	38
374	An expanded universe of cancer targets. <i>Cell</i> , <b>2021</b> , 184, 1142-1155	56.2	38
373	Precision Oncology Decision Support: Current Approaches and Strategies for the Future. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 2719-2731	12.9	37

372	LKB1 is a central regulator of tumor initiation and pro-growth metabolism in ErbB2-mediated breast cancer. <i>Cancer &amp; Metabolism</i> , <b>2013</b> , 1, 18	5.4	37
371	An Integrated Molecular Analysis of Lung Adenocarcinomas Identifies Potential Therapeutic Targets among TTF1-Negative Tumors, Including DNA Repair Proteins and Nrf2. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 3480-91	12.9	36
370	Microenvironment-Mediated Mechanisms of Resistance to HER2 Inhibitors Differ between HER2+ Breast Cancer Subtypes. <i>Cell Systems</i> , <b>2018</b> , 6, 329-342.e6	10.6	36
369	COTI-2, A Novel Thiosemicarbazone Derivative, Exhibits Antitumor Activity in HNSCC through p53-dependent and -independent Mechanisms. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 5650-5662	12.9	36
368	Selective genomic copy number imbalances and probability of recurrence in early-stage breast cancer. <i>PLoS ONE</i> , <b>2011</b> , 6, e23543	3.7	36
367	miRNA551b-3p Activates an Oncostatin Signaling Module for the Progression of Triple-Negative Breast Cancer. <i>Cell Reports</i> , <b>2019</b> , 29, 4389-4406.e10	10.6	36
366	EVI1 splice variants modulate functional responses in ovarian cancer cells. <i>Molecular Oncology</i> , <b>2013</b> , 7, 647-68	7.9	35
365	Targeting KRas-dependent tumour growth, circulating tumour cells and metastasis in vivo by clinically significant miR-193a-3p. <i>Oncogene</i> , <b>2017</b> , 36, 1339-1350	9.2	35
364	Assay of Rab25 function in ovarian and breast cancers. <i>Methods in Enzymology</i> , <b>2005</b> , 403, 202-15	1.7	35
363	Lysophosphatidic acid-induced transcriptional profile represents serous epithelial ovarian carcinoma and worsened prognosis. <i>PLoS ONE</i> , <b>2009</b> , 4, e5583	3.7	35
362	Implementation of biomarker-driven cancer therapy: existing tools and remaining gaps. <i>Discovery Medicine</i> , <b>2014</b> , 17, 101-14	2.5	35
361	Novel patient-derived xenograft and cell line models for therapeutic testing of pediatric liver cancer. <i>Journal of Hepatology</i> , <b>2016</b> , 65, 325-33	13.4	35
360	Dual Src and MEK Inhibition Decreases Ovarian Cancer Growth and Targets Tumor Initiating Stem-Like Cells. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 4874-4886	12.9	35
359	Autotaxin, a lysophospholipase D with pleomorphic effects in oncogenesis and cancer progression. <i>Journal of Lipid Research</i> , <b>2016</b> , 57, 25-35	6.3	34
358	Use of nonsteroidal anti-inflammatory drugs predicts improved patient survival for -altered head and neck cancer. <i>Journal of Experimental Medicine</i> , <b>2019</b> , 216, 419-427	16.6	34
357	Reconstruction of nuclear receptor network reveals that NR2E3 is a novel upstream regulator of ESR1 in breast cancer. <i>EMBO Molecular Medicine</i> , <b>2012</b> , 4, 52-67	12	34
356	Stapled peptide inhibitors of RAB25 target context-specific phenotypes in cancer. <i>Nature Communications</i> , <b>2017</b> , 8, 660	17.4	34
355	Improved prediction of PARP inhibitor response and identification of synergizing agents through use of a novel gene expression signature generation algorithm. <i>Npj Systems Biology and Applications</i> , <b>2017</b> , 3, 8	5	34

354	Copy number gain of hsa-miR-569 at 3q26.2 leads to loss of TP53INP1 and aggressiveness of epithelial cancers. <i>Cancer Cell</i> , <b>2014</b> , 26, 863-879	24.3	34
353	BSTA promotes mTORC2-mediated phosphorylation of Akt1 to suppress expression of FoxC2 and stimulate adipocyte differentiation. <i>Science Signaling</i> , <b>2013</b> , 6, ra2	8.8	34
352	Death-associated protein kinase 1 promotes growth of p53-mutant cancers. <i>Journal of Clinical Investigation</i> , <b>2015</b> , 125, 2707-20	15.9	34
351	The degree of intratumor mutational heterogeneity varies by primary tumor sub-site. <i>Oncotarget</i> , <b>2016</b> , 7, 27185-98	3.3	34
350	Development of a robust classifier for quality control of reverse-phase protein arrays. <i>Bioinformatics</i> , <b>2015</b> , 31, 912-8	7.2	33
349	Systems analysis of apoptotic priming in ovarian cancer identifies vulnerabilities and predictors of drug response. <i>Nature Communications</i> , <b>2017</b> , 8, 365	17.4	33
348	Physical association of PDK1 with AKT1 is sufficient for pathway activation independent of membrane localization and phosphatidylinositol 3 kinase. <i>PLoS ONE</i> , <b>2010</b> , 5, e9910	3.7	33
347	Exploratory analysis of the copy number alterations in glioblastoma multiforme. <i>PLoS ONE</i> , <b>2008</b> , 3, e40767	3.7	33
346	YAP/TAZ-Mediated Upregulation of GAB2 Leads to Increased Sensitivity to Growth Factor-Induced Activation of the PI3K Pathway. <i>Cancer Research</i> , <b>2017</b> , 77, 1637-1648	10.1	32
345	MAPK Activation Predicts Poor Outcome and the MEK Inhibitor, Selumetinib, Reverses Antiestrogen Resistance in ER-Positive High-Grade Serous Ovarian Cancer. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 935-47	12.9	32
344	cMET Activation and EGFR-Directed Therapy Resistance in Triple-Negative Breast Cancer. <i>Journal of Cancer</i> , <b>2014</b> , 5, 745-53	4.5	32
343	Therapeutic potential of phosphoinositide 3-kinase inhibitors. <i>Expert Opinion on Therapeutic Patents</i> , <b>2004</b> , 14, 703-732	6.8	32
342	A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 6468-6477	12.9	31
341	Nuclear PTEN tumor-suppressor functions through maintaining heterochromatin structure. <i>Cell Cycle</i> , <b>2015</b> , 14, 2323-32	4.7	31
340	Induction of competence and progression signals in human T lymphocytes by phorbol esters and calcium ionophores. <i>Journal of Cellular Physiology</i> , <b>1988</b> , 137, 329-36	7	31
339	Bias from removing read duplication in ultra-deep sequencing experiments. <i>Bioinformatics</i> , <b>2014</b> , 30, 1073-1080	7.2	30
338	YB-1 transforms human mammary epithelial cells through chromatin remodeling leading to the development of basal-like breast cancer. <i>Stem Cells</i> , <b>2014</b> , 32, 1437-50	5.8	30
337	Growth suppression of human ovarian cancer cell lines by the introduction of a p16 gene via a recombinant adenovirus. <i>Gynecologic Oncology</i> , <b>1999</b> , 73, 27-34	4.9	30

336	Randomized, placebo-controlled window trial of EGFR, Src, or combined blockade in head and neck cancer. <i>JCI Insight</i> , <b>2017</b> , 2, e90449	9.9	30
335	Loss of ARID1A Activates ANXA1, which Serves as a Predictive Biomarker for Trastuzumab Resistance. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 5238-5248	12.9	30
334	Mig-6 suppresses endometrial cancer associated with Pten deficiency and ERK activation. <i>Cancer Research</i> , <b>2014</b> , 74, 7371-82	10.1	29
333	Specific keynote: genome copy number abnormalities in ovarian cancer. <i>Gynecologic Oncology</i> , <b>2003</b> , 88, S16-21; discussion S22-4	4.9	29
332	Genomic amplicons target vesicle recycling in breast cancer. <i>Journal of Clinical Investigation</i> , <b>2009</b> , 119, 2123-7	15.9	29
331	Proteome Instability Is a Therapeutic Vulnerability in Mismatch Repair-Deficient Cancer. <i>Cancer Cell</i> , <b>2020</b> , 37, 371-386.e12	24.3	28
330	BRD4 amplification facilitates an oncogenic gene expression program in high-grade serous ovarian cancer and confers sensitivity to BET inhibitors. <i>PLoS ONE</i> , <b>2018</b> , 13, e0200826	3.7	28
329	EGFR mediates LPA-induced proteolytic enzyme expression and ovarian cancer invasion: inhibition by resveratrol. <i>Molecular Oncology</i> , <b>2013</b> , 7, 121-9	7.9	28
328	Retrospective Review of MET Gene Mutations. <i>Oncoscience</i> , <b>2015</b> , 2, 533-41	0.8	28
327	LMW-E/CDK2 deregulates acinar morphogenesis, induces tumorigenesis, and associates with the activated b-Raf-ERK1/2-mTOR pathway in breast cancer patients. <i>PLoS Genetics</i> , <b>2012</b> , 8, e1002538	6	28
326	Transmembrane signaling by the interleukin-2 receptor: progress and conundrums. <i>Seminars in Immunology</i> , <b>1993</b> , 5, 345-64	10.7	28
325	Expression of ras oncogene leads to down-regulation of protein kinase C. <i>International Journal of Cancer</i> , <b>1990</b> , 45, 1177-83	7.5	28
324	Rab25 acts as an oncogene in luminal B breast cancer and is causally associated with Snail driven EMT. <i>Oncotarget</i> , <b>2016</b> , 7, 40252-40265	3.3	28
323	Molecular Analysis of Clinically Defined Subsets of High-Grade Serous Ovarian Cancer. <i>Cell Reports</i> , <b>2020</b> , 31, 107502	10.6	28
322	Association of Somatic Mutations of ADAMTS Genes With Chemotherapy Sensitivity and Survival in High-Grade Serous Ovarian Carcinoma. <i>JAMA Oncology</i> , <b>2015</b> , 1, 486-94	13.4	27
321	A curated census of autophagy-modulating proteins and small molecules: candidate targets for cancer therapy. <i>Autophagy</i> , <b>2014</b> , 10, 1316-26	10.2	27
320	Proteomic characterization of breast cancer xenografts identifies early and late bevacizumab-induced responses and predicts effective drug combinations. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 404-12	12.9	27
319	Lysophosphatidic acid induces lymphangiogenesis and IL-8 production in vitro in human lymphatic endothelial cells. <i>American Journal of Pathology</i> , <b>2012</b> , 180, 2170-81	5.8	27

318	Dissecting "PI3Kness": the complexity of personalized therapy for ovarian cancer. <i>Cancer Discovery</i> , <b>2012</b> , 2, 16-8	24.4	27
317	Lysophosphatidic acid (LPA)-induced vasodilator-stimulated phosphoprotein mediates lamellipodia formation to initiate motility in PC-3 prostate cancer cells. <i>Molecular Oncology</i> , <b>2008</b> , 2, 54-69	7.9	27
316	Stem cell-ness: a "magic marker" for cancer. <i>Journal of Clinical Investigation</i> , <b>2005</b> , 115, 1463-7	15.9	27
315	Functional consequence of the MET-T1010I polymorphism in breast cancer. <i>Oncotarget</i> , <b>2015</b> , 6, 2604-14	5.3	27
314	Neomorphic PDGFRA extracellular domain driver mutations are resistant to PDGFRA targeted therapies. <i>Nature Communications</i> , <b>2018</b> , 9, 4583	17.4	27
313	Combined MEK and BCL-2/X Inhibition Is Effective in High-Grade Serous Ovarian Cancer Patient-Derived Xenograft Models and BIM Levels Are Predictive of Responsiveness. <i>Molecular Cancer Therapeutics</i> , <b>2019</b> , 18, 642-655	6.1	26
312	Multigene clinical mutational profiling of breast carcinoma using next-generation sequencing. <i>American Journal of Clinical Pathology</i> , <b>2015</b> , 144, 713-21	1.9	26
311	Rab25 augments cancer cell invasiveness through a $\beta$ 1 integrin/EGFR/VEGF-A/Snail signaling axis and expression of fascin. <i>Experimental and Molecular Medicine</i> , <b>2018</b> , 50, e435	12.8	26
310	LYN-activating mutations mediate antiestrogen resistance in estrogen receptor-positive breast cancer. <i>Journal of Clinical Investigation</i> , <b>2014</b> , 124, 5490-502	15.9	26
309	SU2C phase Ib study of paclitaxel and MK-2206 in advanced solid tumors and metastatic breast cancer. <i>Journal of the National Cancer Institute</i> , <b>2015</b> , 107,	9.7	26
308	Systematic analysis of genotype-specific drug responses in cancer. <i>International Journal of Cancer</i> , <b>2012</b> , 131, 2456-64	7.5	26
307	Lysophosphatidic acid signaling protects pulmonary vasculature from hypoxia-induced remodeling. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2012</b> , 32, 24-32	9.4	26
306	Neither the LCK nor the FYN kinases are obligatory for IL-2-mediated signal transduction in HTLV-I-infected human T cells. <i>International Immunology</i> , <b>1992</b> , 4, 1233-43	4.9	26
305	High Intratumoral Stromal Content Defines Reactive Breast Cancer as a Low-risk Breast Cancer Subtype. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 5068-5078	12.9	26
304	Context Specificity in Causal Signaling Networks Revealed by Phosphoprotein Profiling. <i>Cell Systems</i> , <b>2017</b> , 4, 73-83.e10	10.6	25
303	Oncogenic RAS Regulates Long Noncoding RNA in Human Cancer. <i>Cancer Research</i> , <b>2017</b> , 77, 3745-3757	10.1	25
302	TCPA v3.0: An Integrative Platform to Explore the Pan-Cancer Analysis of Functional Proteomic Data. <i>Molecular and Cellular Proteomics</i> , <b>2019</b> , 18, S15-S25	7.6	25
301	Ex Vivo Confocal Fluorescence Microscopy for Rapid Evaluation of Tissues in Surgical Pathology Practice. <i>Archives of Pathology and Laboratory Medicine</i> , <b>2018</b> , 142, 396-401	5	25

300	HSP70 Inhibition Limits FAK-Dependent Invasion and Enhances the Response to Melanoma Treatment with BRAF Inhibitors. <i>Cancer Research</i> , <b>2016</b> , 76, 2720-30	10.1	25
299	Next-Generation Sequencing and Result Interpretation in Clinical Oncology: Challenges of Personalized Cancer Therapy. <i>Annual Review of Medicine</i> , <b>2017</b> , 68, 113-125	17.4	25
298	A-to-I-edited miRNA-379-5p inhibits cancer cell proliferation through CD97-induced apoptosis. <i>Journal of Clinical Investigation</i> , <b>2019</b> , 129, 5343-5356	15.9	25
297	Abortive autophagy induces endoplasmic reticulum stress and cell death in cancer cells. <i>PLoS ONE</i> , <b>2012</b> , 7, e39400	3.7	25
296	Verteporfin Inhibits PD-L1 through Autophagy and the STAT1-IRF1-TRIM28 Signaling Axis, Exerting Antitumor Efficacy. <i>Cancer Immunology Research</i> , <b>2020</b> , 8, 952-965	12.5	25
295	Implementing a comprehensive translational oncology platform: from molecular testing to actionability. <i>Journal of Translational Medicine</i> , <b>2018</b> , 16, 358	8.5	25
294	Integrated analysis reveals microRNA networks coordinately expressed with key proteins in breast cancer. <i>Genome Medicine</i> , <b>2015</b> , 7, 21	14.4	24
293	Modulation of Breast Cancer Risk Biomarkers by High-Dose Omega-3 Fatty Acids: Phase II Pilot Study in Premenopausal Women. <i>Cancer Prevention Research</i> , <b>2015</b> , 8, 912-21	3.2	24
292	Modulation of Breast Cancer Risk Biomarkers by High-Dose Omega-3 Fatty Acids: Phase II Pilot Study in Postmenopausal Women. <i>Cancer Prevention Research</i> , <b>2015</b> , 8, 922-31	3.2	24
291	Cardiac glycosides display selective efficacy for STK11 mutant lung cancer. <i>Scientific Reports</i> , <b>2016</b> , 6, 29721	4.9	24
290	Targeting therapeutic liabilities engendered by PIK3R1 mutations for cancer treatment. <i>Pharmacogenomics</i> , <b>2016</b> , 17, 297-307	2.6	24
289	RCP induces Slug expression and cancer cell invasion by stabilizing $\beta$ integrin. <i>Oncogene</i> , <b>2017</b> , 36, 1102-1111	11.1	24
288	Activation of p21(CIP1/WAF1) in mammary epithelium accelerates mammary tumorigenesis and promotes lung metastasis. <i>Biochemical and Biophysical Research Communications</i> , <b>2010</b> , 403, 103-7	3.4	24
287	Methylation and messenger RNA expression of p15INK4b but not p16INK4a are independent risk factors for ovarian cancer. <i>Clinical Cancer Research</i> , <b>2005</b> , 11, 4968-76	12.9	24
286	p202 prevents apoptosis in murine AKR-2B fibroblasts. <i>Biochemical and Biophysical Research Communications</i> , <b>1998</b> , 247, 379-82	3.4	24
285	Inhibition of the ATM/Chk2 axis promotes cGAS/STING signaling in ARID1A-deficient tumors. <i>Journal of Clinical Investigation</i> , <b>2020</b> , 130, 5951-5966	15.9	24
284	Comprehensive assessment of computational algorithms in predicting cancer driver mutations. <i>Genome Biology</i> , <b>2020</b> , 21, 43	18.3	23
283	Rab11-FIP1C Is a Critical Negative Regulator in ErbB2-Mediated Mammary Tumor Progression. <i>Cancer Research</i> , <b>2016</b> , 76, 2662-74	10.1	23

282	"Personalized Cancer Therapy": A Publicly Available Precision Oncology Resource. <i>Cancer Research</i> , <b>2017</b> , 77, e123-e126	10.1	23
281	Cetuximab attenuates metastasis and u-PAR expression in non-small cell lung cancer: u-PAR and E-cadherin are novel biomarkers of cetuximab sensitivity. <i>Cancer Research</i> , <b>2009</b> , 69, 2461-70	10.1	23
280	Point mutations of protein kinases and individualised cancer therapy. <i>Expert Opinion on Pharmacotherapy</i> , <b>2006</b> , 7, 2243-61	4	23
279	Autophosphorylation of Akt at threonine 72 and serine 246. A potential mechanism of regulation of Akt kinase activity. <i>Journal of Biological Chemistry</i> , <b>2006</b> , 281, 13837-13843	5.4	23
278	Proteomic analysis of circulating extracellular vesicles identifies potential markers of breast cancer progression, recurrence, and response. <i>Science Advances</i> , <b>2020</b> , 6,	14.3	23
277	Survival Outcomes by Mutation Status in Metastatic Breast Cancer. <i>JCO Precision Oncology</i> , <b>2018</b> , 2018,	3.6	23
276	Defective Replication Stress Response Is Inherently Linked to the Cancer Stem Cell Phenotype. <i>Cell Reports</i> , <b>2018</b> , 23, 2095-2106	10.6	23
275	Engineering and Functional Characterization of Fusion Genes Identifies Novel Oncogenic Drivers of Cancer. <i>Cancer Research</i> , <b>2017</b> , 77, 3502-3512	10.1	22
274	Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference. <i>Cancer</i> , <b>2019</b> , 125, 1963-1972	6.4	22
273	Survival of Cancer Stem-Like Cells Under Metabolic Stress via CaMK2 $\beta$ -mediated Upregulation of Sarco/Endoplasmic Reticulum Calcium ATPase Expression. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 1677-1690	12.9	22
272	Loss-of-function screens of druggable targetome against cancer stem-like cells. <i>FASEB Journal</i> , <b>2017</b> , 31, 625-635	0.9	22
271	ZNF668 functions as a tumor suppressor by regulating p53 stability and function in breast cancer. <i>Cancer Research</i> , <b>2011</b> , 71, 6524-34	10.1	22
270	Overexpression of SnoN/SkiL, amplified at the 3q26.2 locus, in ovarian cancers: a role in ovarian pathogenesis. <i>Molecular Oncology</i> , <b>2008</b> , 2, 164-81	7.9	22
269	Chk1 inhibition potentiates the therapeutic efficacy of PARP inhibitor BMN673 in gastric cancer. <i>American Journal of Cancer Research</i> , <b>2017</b> , 7, 473-483	4.4	22
268	Deregulated Gab2 phosphorylation mediates aberrant AKT and STAT3 signaling upon PIK3R1 loss in ovarian cancer. <i>Nature Communications</i> , <b>2019</b> , 10, 716	17.4	22
267	Epigenetic Regulation of KPC1 Ubiquitin Ligase Affects the NF- $\kappa$ B Pathway in Melanoma. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 4831-4842	12.9	21
266	Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 4771-4784	12.9	21
265	Suppression of p16 Induces mTORC1-Mediated Nucleotide Metabolic Reprogramming. <i>Cell Reports</i> , <b>2019</b> , 28, 1971-1980.e8	10.6	21



264	Agents that stabilize mutated von Hippel-Lindau (VHL) protein: results of a high-throughput screen to identify compounds that modulate VHL proteostasis. <i>Journal of Biomolecular Screening</i> , <b>2012</b> , 17, 572-80		21
263	Specific keynote: molecular therapeutics in ovarian cancer. <i>Gynecologic Oncology</i> , <b>2003</b> , 88, S88-92; discussion S93-6	4.9	21
262	Levels of soluble interleukin-2 receptor-alpha are elevated in serum and ascitic fluid from epithelial ovarian cancer patients. <i>American Journal of Obstetrics and Gynecology</i> , <b>1994</b> , 170, 918-28	6.4	21
261	Predicting time to ovarian carcinoma recurrence using protein markers. <i>Journal of Clinical Investigation</i> , <b>2013</b> , 123, 5410-5410	15.9	21
260	Hotspot mutations delineating diverse mutational signatures and biological utilities across cancer types. <i>BMC Genomics</i> , <b>2016</b> , 17 Suppl 2, 394	4.5	21
259	The tumour suppressor OPCML promotes AXL inactivation by the phosphatase PTPRG in ovarian cancer. <i>EMBO Reports</i> , <b>2018</b> , 19,	6.5	20
258	ATG5 Mediates a Positive Feedback Loop between Wnt Signaling and Autophagy in Melanoma. <i>Cancer Research</i> , <b>2017</b> , 77, 5873-5885	10.1	20
257	Polymorphisms in the survivin promoter are associated with age of onset of ovarian cancer. <i>International Journal of Clinical and Experimental Medicine</i> , <b>2009</b> , 2, 289-99		20
256	MCP-1/CCR-2 axis in adipocytes and cancer cell respectively facilitates ovarian cancer peritoneal metastasis. <i>Oncogene</i> , <b>2020</b> , 39, 1681-1695	9.2	20
255	Transgenic Expression of the Mitochondrial Chaperone TNFR-associated Protein 1 (TRAP1) Accelerates Prostate Cancer Development. <i>Journal of Biological Chemistry</i> , <b>2016</b> , 291, 25247-25254	5.4	19
254	Integrative Protein-Based Prognostic Model for Early-Stage Endometrioid Endometrial Cancer. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 513-23	12.9	19
253	Proteomic Features of Colorectal Cancer Identify Tumor Subtypes Independent of Oncogenic Mutations and Independently Predict Relapse-Free Survival. <i>Annals of Surgical Oncology</i> , <b>2017</b> , 24, 4051-4058	21	19
252	Neomorphic mutations create therapeutic challenges in cancer. <i>Oncogene</i> , <b>2017</b> , 36, 1607-1618	9.2	19
251	Location, location, location: a crystal-clear view of autotaxin saturating LPA receptors. <i>Nature Structural and Molecular Biology</i> , <b>2011</b> , 18, 117-8	17.6	19
250	Cadherin endocytosis. <i>Nature Reviews Cancer</i> , <b>2009</b> , 9, 143-143	31.3	19
249	Reverse phase protein array identifies novel anti-invasion mechanisms of YC-1. <i>Biochemical Pharmacology</i> , <b>2010</b> , 79, 842-52	6	19
248	The rebirth of a phoenix: ovarian cancers are addicted to ErbB-3. <i>Cancer Cell</i> , <b>2010</b> , 17, 217-8	24.3	19
247	Synthesis and pharmacological evaluation of the stereoisomers of 3-carba cyclic-phosphatidic acid. <i>Bioorganic and Medicinal Chemistry Letters</i> , <b>2010</b> , 20, 7525-8	2.9	19

246	Opportunities and challenges in ovarian cancer research, a perspective from the 11th Ovarian cancer action/HHMT Forum, Lake Como, March 2007. <i>Gynecologic Oncology</i> , <b>2008</b> , 108, 652-7	4.9	19
245	Molecular therapeutics: promise and challenges. <i>Seminars in Oncology</i> , <b>2004</b> , 31, 39-53	5.5	19
244	Characteristics of percutaneous core biopsies adequate for next generation genomic sequencing. <i>PLoS ONE</i> , <b>2017</b> , 12, e0189651	3.7	19
243	Messenger RNA expression and methylation of candidate tumor-suppressor genes and risk of ovarian cancer-a case-control analysis. <i>International Journal of Molecular Epidemiology and Genetics</i> , <b>2010</b> , 1, 1-10	0.9	19
242	Phase II, 2-stage, 2-arm, PIK3CA mutation stratified trial of MK-2206 in recurrent endometrial cancer. <i>International Journal of Cancer</i> , <b>2020</b> , 147, 413-422	7.5	19
241	Patient derived mutation W257G of PPP2R1A enhances cancer cell migration through SRC-JNK-c-Jun pathway. <i>Scientific Reports</i> , <b>2016</b> , 6, 27391	4.9	19
240	Protein Kinase C Quality Control by Phosphatase PHLPP1 Unveils Loss-of-Function Mechanism in Cancer. <i>Molecular Cell</i> , <b>2019</b> , 74, 378-392.e5	17.6	18
239	RNA-binding protein NONO contributes to cancer cell growth and confers drug resistance as a theranostic target in TNBC. <i>Theranostics</i> , <b>2020</b> , 10, 7974-7992	12.1	18
238	In vivo screening identifies GATAD2B as a metastasis driver in KRAS-driven lung cancer. <i>Nature Communications</i> , <b>2018</b> , 9, 2732	17.4	18
237	AKT isoform-specific expression and activation across cancer lineages. <i>BMC Cancer</i> , <b>2018</b> , 18, 742	4.8	18
236	Safety lead-in of the MEK inhibitor trametinib in combination with GSK2141795, an AKT inhibitor, in patients with recurrent endometrial cancer: An NRG Oncology/GOG study. <i>Gynecologic Oncology</i> , <b>2019</b> , 155, 420-428	4.9	18
235	Genetic and pharmacological strategies to refunctionalize the von Hippel Lindau R167Q mutant protein. <i>Cancer Research</i> , <b>2014</b> , 74, 3127-36	10.1	18
234	Association between germline single nucleotide polymorphisms in the PI3K-AKT-mTOR pathway, obesity, and breast cancer disease-free survival. <i>Breast Cancer Research and Treatment</i> , <b>2014</b> , 147, 381-7	4.4	18
233	Unique protein expression signatures of survival time in kidney renal clear cell carcinoma through a pan-cancer screening. <i>BMC Genomics</i> , <b>2017</b> , 18, 678	4.5	18
232	Spatial normalization of reverse phase protein array data. <i>PLoS ONE</i> , <b>2014</b> , 9, e97213	3.7	18
231	An emerging toolkit for targeted cancer therapies. <i>Genome Research</i> , <b>2012</b> , 22, 177-82	9.7	18
230	Small molecule ErbB inhibitors decrease proliferative signaling and promote apoptosis in philadelphia chromosome-positive acute lymphoblastic leukemia. <i>PLoS ONE</i> , <b>2013</b> , 8, e70608	3.7	18
229	Homozygous deletion of glycogen synthase kinase 3beta bypasses senescence allowing Ras transformation of primary murine fibroblasts. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2008</b> , 105, 5248-53	11.5	18

228	Clinical outcomes based on multigene profiling in metastatic breast cancer patients. <i>Oncotarget</i> , <b>2016</b> , 7, 76362-76373	3.3	18
227	Targeting tyrosine-kinases and estrogen receptor abrogates resistance to endocrine therapy in breast cancer. <i>Oncotarget</i> , <b>2014</b> , 5, 9049-64	3.3	18
226	A putative biomarker signature for clinically effective AKT inhibition: correlation of in vitro, in vivo and clinical data identifies the importance of modulation of the mTORC1 pathway. <i>Oncotarget</i> , <b>2015</b> , 6, 41736-49	3.3	18
225	Synthetic lethal combination targeting BET uncovered intrinsic susceptibility of TNBC to ferroptosis. <i>Science Advances</i> , <b>2020</b> , 6,	14.3	18
224	Analysis of phosphatases in ER-negative breast cancers identifies DUSP4 as a critical regulator of growth and invasion. <i>Breast Cancer Research and Treatment</i> , <b>2016</b> , 158, 441-54	4.4	18
223	A comprehensive comparison of normalization methods for loading control and variance stabilization of reverse-phase protein array data. <i>Cancer Informatics</i> , <b>2014</b> , 13, 109-17	2.4	17
222	Interactions between tumor cells and microenvironment in breast cancer: a new opportunity for targeted therapy. <i>Cancer Science</i> , <b>2012</b> , 103, 400-7	6.9	17
221	Bioinformatics and systems biology. <i>Molecular Oncology</i> , <b>2012</b> , 6, 147-54	7.9	17
220	Interleukin-2 reverses the defect in activation-induced apoptosis in T cells from autoimmune lpr mice. <i>Cellular Immunology</i> , <b>1998</b> , 183, 1-12	4.4	17
219	Modulators of lysophosphatidic acid signalling. <i>Expert Opinion on Therapeutic Patents</i> , <b>2003</b> , 13, 1619-1634	3.4	17
218	Transfection of human ovarian cancer cells with the HER-2/neu receptor tyrosine kinase induces a selective increase in PTP-H1, PTP-1B, PTP-alpha expression. <i>Gynecologic Oncology</i> , <b>1996</b> , 61, 233-40	4.9	17
217	Clinical relevance of TP53 hotspot mutations in high-grade serous ovarian cancers. <i>British Journal of Cancer</i> , <b>2020</b> , 122, 405-412	8.7	17
216	Analysis of Ugandan cervical carcinomas identifies human papillomavirus clade-specific epigenome and transcriptome landscapes. <i>Nature Genetics</i> , <b>2020</b> , 52, 800-810	36.3	17
215	Systems biology approach reveals a link between mTORC1 and G2/M DNA damage checkpoint recovery. <i>Nature Communications</i> , <b>2018</b> , 9, 3982	17.4	17
214	Differences in gene and protein expression and the effects of race/ethnicity on breast cancer subtypes. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2014</b> , 23, 316-23	4	16
213	p202 self-associates through a sequence conserved among the members of the 200-family proteins. <i>FEBS Letters</i> , <b>1998</b> , 438, 21-4	3.8	16
212	Physiologic and pathologic drug resistance in ovarian carcinoma--a hypothesis based on a clonal progression model. <i>Acta Oncologica</i> , <b>1998</b> , 37, 629-40	3.2	16
211	Soluble interleukin-2 receptor alpha is elevated in sera of patients with benign ovarian neoplasms and epithelial ovarian cancer. <i>Cancer</i> , <b>1995</b> , 76, 1615-20	6.4	16

210	Decoupling of the PI3K Pathway via Mutation Necessitates Combinatorial Treatment in HER2+ Breast Cancer. <i>PLoS ONE</i> , <b>2015</b> , 10, e0133219	3.7	16
209	MERIT: Systematic Analysis and Characterization of Mutational Effect on RNA Interactome Topology. <i>Hepatology</i> , <b>2019</b> , 70, 532-546	11.2	16
208	Genome-Wide Analysis of Head and Neck Squamous Cell Carcinomas Reveals HPV, TP53, Smoking and Alcohol-Related Allele-Based Acquired Uniparental Disomy Genomic Alterations. <i>Neoplasia</i> , <b>2019</b> , 21, 197-205	6.4	16
207	Precision oncology: neither a silver bullet nor a dream. <i>Pharmacogenomics</i> , <b>2017</b> , 18, 1525-1539	2.6	15
206	Fibroblast-tumor cell signaling limits HER2 kinase therapy response via activation of MTOR and antiapoptotic pathways. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2020</b> , 117, 16500-16508	11.5	15
205	Clinical Use of Precision Oncology Decision Support. <i>JCO Precision Oncology</i> , <b>2017</b> , 2017,	3.6	15
204	Implementation of a Multiplex and Quantitative Proteomics Platform for Assessing Protein Lysates Using DNA-Barcoded Antibodies. <i>Molecular and Cellular Proteomics</i> , <b>2018</b> , 17, 1245-1258	7.6	15
203	A systems approach to analysis of molecular complexity in breast cancer. <i>Clinical Cancer Research</i> , <b>2009</b> , 15, 417-9	12.9	15
202	Network topology determines dynamics of the mammalian MAPK1,2 signaling network: bifan motif regulation of C-Raf and B-Raf isoforms by FGFR and MC1R. <i>FASEB Journal</i> , <b>2008</b> , 22, 1393-403	0.9	15
201	Identification of tissue- and cancer-selective promoters for the introduction of genes into human ovarian cancer cells. <i>Gynecologic Oncology</i> , <b>2002</b> , 85, 451-8	4.9	15
200	Functional comparison of recombinant interleukin 2 (IL-2) with IL-2-containing preparations derived from cultured cells. <i>Cellular Immunology</i> , <b>1985</b> , 95, 146-56	4.4	15
199	Targeting mitochondria in cancer therapy could provide a basis for the selective anti-cancer activity. <i>PLoS ONE</i> , <b>2019</b> , 14, e0205623	3.7	14
198	The rise of genomic profiling in ovarian cancer. <i>Expert Review of Molecular Diagnostics</i> , <b>2016</b> , 16, 1337-1358	3.8	14
197	PIK3CA exon9 mutations associate with reduced survival, and are highly concordant between matching primary tumors and metastases in endometrial cancer. <i>Scientific Reports</i> , <b>2017</b> , 7, 10240	4.9	14
196	Niche-localized tumor cells are protected from HER2-targeted therapy via upregulation of an anti-apoptotic program in vivo. <i>Npj Breast Cancer</i> , <b>2017</b> , 3, 18	7.8	14
195	Data integration gets 'Sloppy'. <i>Nature Biotechnology</i> , <b>2006</b> , 24, 1070-1	44.5	14
194	The tyrosine kinase activity of the C-erbB-2 gene product (p185) is required for growth inhibition by anti-p185 antibodies but not for the cytotoxicity of an anti-p185-ricin-A chain immunotoxin. <i>International Journal of Cancer</i> , <b>1994</b> , 59, 242-7	7.5	14
193	T-lymphocyte proliferation: tyrosine kinases in interleukin 2 signal transduction. <i>Best Practice and Research: Clinical Haematology</i> , <b>1992</b> , 5, 551-73		14

192	Response of human B cells to different anti-immunoglobulin isotypes: absence of a correlation between early activation events and cell proliferation. <i>European Journal of Immunology</i> , <b>1987</b> , 17, 1737-42	6.1	14
191	Dynamic clonal remodelling in breast cancer metastases is associated with subtype conversion. <i>European Journal of Cancer</i> , <b>2019</b> , 120, 54-64	7.5	13
190	Prognostic relevance of acquired uniparental disomy in serous ovarian cancer. <i>Molecular Cancer</i> , <b>2015</b> , 14, 29	42.1	13
189	Large-Scale Characterization of Drug Responses of Clinically Relevant Proteins in Cancer Cell Lines. <i>Cancer Cell</i> , <b>2020</b> , 38, 829-843.e4	24.3	13
188	Downregulation of the Ubiquitin-E3 Ligase RNF123 Promotes Upregulation of the NF- $\kappa$ B1 Target SerpinE1 in Aggressive Glioblastoma Tumors. <i>Cancers</i> , <b>2020</b> , 12,	6.6	13
187	Detection of breast cancer stem cell gene mutations in circulating free DNA during the evolution of metastases. <i>Breast Cancer Research and Treatment</i> , <b>2019</b> , 178, 251-261	4.4	13
186	The phosphatase PPM1A inhibits triple negative breast cancer growth by blocking cell cycle progression. <i>Npj Breast Cancer</i> , <b>2019</b> , 5, 22	7.8	13
185	A time-series DDP for functional proteomics profiles. <i>Biometrics</i> , <b>2012</b> , 68, 859-68	1.8	13
184	Clinical investigation of receptor and non-receptor tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer. <i>Expert Opinion on Pharmacotherapy</i> , <b>2013</b> , 14, 2171-82	4	13
183	Activation of murine double minute 2 by Akt in mammary epithelium delays mammary involution and accelerates mammary tumorigenesis. <i>Cancer Research</i> , <b>2010</b> , 70, 7684-9	10.1	13
182	Induction of papillary carcinoma in human ovarian surface epithelial cells using combined genetic elements and peritoneal microenvironment. <i>Cell Cycle</i> , <b>2010</b> , 9, 140-6	4.7	13
181	Interrelationship between signals transduced by phytohemagglutinin and interleukin 1. <i>Journal of Cellular Physiology</i> , <b>1990</b> , 142, 539-51	7	13
180	Systems approach to rational combination therapy: PARP inhibitors. <i>Biochemical Society Transactions</i> , <b>2020</b> , 48, 1101-1108	5.1	13
179	High multiplex, digital spatial profiling of proteins and RNA in fixed tissue using genomic detection methods		13
178	Adaptive responses in a PARP inhibitor window of opportunity trial illustrate limited functional interlesional heterogeneity and potential combination therapy options. <i>Oncotarget</i> , <b>2019</b> , 10, 3533-3546	3.3	12
177	GPNMB augments Wnt-1 mediated breast tumor initiation and growth by enhancing PI3K/AKT/mTOR pathway signaling and Eatenin activity. <i>Oncogene</i> , <b>2019</b> , 38, 5294-5307	9.2	12
176	Upregulation of cell surface GD3 ganglioside phenotype is associated with human melanoma brain metastasis. <i>Molecular Oncology</i> , <b>2020</b> , 14, 1760-1778	7.9	12
175	Preclinical evaluation and reverse phase protein Array-based profiling of PI3K and MEK inhibitors in endometrial carcinoma in vitro. <i>BMC Cancer</i> , <b>2018</b> , 18, 168	4.8	12

174	Frequency of mutations and polymorphisms in borderline ovarian tumors of known cancer genes. <i>Modern Pathology</i> , <b>2013</b> , 26, 544-52	9.8	12
173	Identification of remodeling and spacing factor 1 (rsf-1, HBXAP) at chromosome 11q13 as a putative oncogene in ovarian cancer. <i>European Journal of Human Genetics</i> , <b>2006</b> , 14, 381-3	5.3	12
172	Role of protein kinase C in interleukin 1, anti-T3, and mitogenic lectin-induced interleukin 2 secretion. <i>Journal of Cellular Physiology</i> , <b>1989</b> , 141, 310-7	7	12
171	A feasibility study of returning clinically actionable somatic genomic alterations identified in a research laboratory. <i>Oncotarget</i> , <b>2017</b> , 8, 41806-41814	3.3	12
170	Homeostasis of redox status derived from glucose metabolic pathway could be the key to understanding the Warburg effect. <i>American Journal of Cancer Research</i> , <b>2015</b> , 5, 928-44	4.4	12
169	BRCA1 Promoter Methylation and Clinical Outcomes in Ovarian Cancer: An Individual Patient Data Meta-Analysis. <i>Journal of the National Cancer Institute</i> , <b>2020</b> , 112, 1190-1203	9.7	12
168	Landscapes of cellular phenotypic diversity in breast cancer xenografts and their impact on drug response. <i>Nature Communications</i> , <b>2021</b> , 12, 1998	17.4	12
167	Molecular mechanisms and pathobiology of oncogenic fusion transcripts in epithelial tumors. <i>Oncotarget</i> , <b>2019</b> , 10, 2095-2111	3.3	11
166	Molecular heterogeneity at the network level: high-dimensional testing, clustering and a TCGA case study. <i>Bioinformatics</i> , <b>2017</b> , 33, 2890-2896	7.2	10
165	Advancing Drug Development in Gynecologic Malignancies. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 4874-4880	2.9	10
164	Gene Regulatory Network Perturbation by Genetic and Epigenetic Variation. <i>Trends in Biochemical Sciences</i> , <b>2018</b> , 43, 576-592	10.3	10
163	Integrated analysis of transcriptomes of cancer cell lines and patient samples reveals STK11/LKB1-driven regulation of cAMP phosphodiesterase-4D. <i>Molecular Cancer Therapeutics</i> , <b>2014</b> , 13, 2463-73	6.1	10
162	Differential expression of MAGEA6 toggles autophagy to promote pancreatic cancer progression. <i>ELife</i> , <b>2020</b> , 9,	8.9	10
161	Hormonal modulation of ESR1 mutant metastasis. <i>Oncogene</i> , <b>2021</b> , 40, 997-1011	9.2	10
160	Association Between Sex and Immune-Related Adverse Events During Immune Checkpoint Inhibitor Therapy. <i>Journal of the National Cancer Institute</i> , <b>2021</b> , 113, 1396-1404	9.7	10
159	Glutaminase inhibition with telaglenastat (CB-839) improves treatment response in combination with ionizing radiation in head and neck squamous cell carcinoma models. <i>Cancer Letters</i> , <b>2021</b> , 502, 180-188	9.8	10
158	In Situ Tumor Vaccination with Nanoparticle Co-Delivering CpG and STAT3 siRNA to Effectively Induce Whole-Body Antitumor Immune Response. <i>Advanced Materials</i> , <b>2021</b> , 33, e2100628	24	10
157	The management of malignant ascites and impact on quality of life outcomes in women with ovarian cancer. <i>Expert Review of Quality of Life in Cancer Care</i> , <b>2016</b> , 1, 231-238		10

156	Confocal Fluorescence Microscopy Platform Suitable for Rapid Evaluation of Small Fragments of Tissue in Surgical Pathology Practice. <i>Archives of Pathology and Laboratory Medicine</i> , <b>2019</b> , 143, 305-313	5	10
155	Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 3720-3731	12.9	10
154	Surviving Ovarian Cancer: An Affair between Defective DNA Repair and RB1. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 508-510	12.9	10
153	Autotaxin exacerbates tumor progression by enhancing MEK1 and overriding the function of miR-489-3p. <i>Cancer Letters</i> , <b>2018</b> , 432, 84-92	9.9	10
152	Results of an abbreviated phase II study of AKT inhibitor MK-2206 in the treatment of recurrent platinum-resistant high grade serous ovarian, fallopian tube, or primary peritoneal carcinoma (NCT 01283035). <i>Gynecologic Oncology Reports</i> , <b>2020</b> , 32, 100546	1.3	9
151	AKT pathway genes define 5 prognostic subgroups in glioblastoma. <i>PLoS ONE</i> , <b>2014</b> , 9, e100827	3.7	9
150	Lymphocyte function in human bone marrow. II. Characterization of an interleukin 2-sensitive T precursor-cell population. <i>Journal of Clinical Immunology</i> , <b>1985</b> , 5, 345-56	5.7	9
149	Homeostasis of redox status derived from glucose metabolic pathway could be the key to understanding the Warburg effect. <i>American Journal of Cancer Research</i> , <b>2015</b> , 5, 1265-80	4.4	9
148	MAPK pathway mutations in head and neck cancer affect immune microenvironments and ErbB3 signaling. <i>Life Science Alliance</i> , <b>2020</b> , 3,	5.8	9
147	Transient commensal clonal interactions can drive tumor metastasis. <i>Nature Communications</i> , <b>2020</b> , 11, 5799	17.4	9
146	Targeting Extracellular Matrix Remodeling Restores BRAF Inhibitor Sensitivity in BRAFi-resistant Melanoma. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 6039-6050	12.9	9
145	Amplification Associates with Aggressive Phenotype but Not Markers of AKT-MTOR Signaling in Endometrial Carcinoma. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 334-345	12.9	9
144	Therapy resistance: opportunities created by adaptive responses to targeted therapies in cancer.. <i>Nature Reviews Cancer</i> , <b>2022</b> ,	31.3	9
143	Predicting Cancer Cell Line Dependencies From the Protein Expression Data of Reverse-Phase Protein Arrays. <i>JCO Clinical Cancer Informatics</i> , <b>2020</b> , 4, 357-366	5.2	8
142	Eatenin/TCF activity regulates IGF-1R tyrosine kinase inhibitor sensitivity in colon cancer. <i>Oncogene</i> , <b>2018</b> , 37, 5466-5475	9.2	8
141	Cancer driver mutation prediction through Bayesian integration of multi-omic data. <i>PLoS ONE</i> , <b>2018</b> , 13, e0196939	3.7	8
140	Detection algorithm for the validation of human cell lines. <i>International Journal of Cancer</i> , <b>2012</b> , 131, E1024-30	7.5	8
139	Molecular screening for breast cancer prevention, early detection, and treatment planning: combining biomarkers from DNA, RNA, and protein. <i>Current Oncology Reports</i> , <b>2006</b> , 8, 484-91	6.3	8

138	Functional evidence for an ovarian cancer tumor suppressor gene on chromosome 22 by microcell-mediated chromosome transfer. <i>Oncogene</i> , <b>2000</b> , 19, 6277-85	9.2	8
137	Interleukin 2 in cell-mediated immune responses. <i>Journal of Supramolecular Structure</i> , <b>1980</b> , 13, 271-80		8
136	Robust Selection Algorithm (RSA) for Multi-Omic Biomarker Discovery; Integration with Functional Network Analysis to Identify miRNA Regulated Pathways in Multiple Cancers. <i>PLoS ONE</i> , <b>2015</b> , 10, e0140072	3.7	8
135	Genomic analysis of exceptional responder to regorafenib in treatment-refractory metastatic rectal cancer: a case report and review of the literature. <i>Oncotarget</i> , <b>2017</b> , 8, 57882-57888	3.3	8
134	Relevance of circulating hybrid cells as a non-invasive biomarker for myriad solid tumors. <i>Scientific Reports</i> , <b>2021</b> , 11, 13630	4.9	8
133	Physician interpretation of genomic test results and treatment selection. <i>Cancer</i> , <b>2018</b> , 124, 966-972	6.4	8
132	Loss of Phd2 cooperates with BRAF to drive melanomagenesis. <i>Nature Communications</i> , <b>2018</b> , 9, 5426	17.4	8
131	Mechanisms underlying chemoprevention of ovarian cancer. <i>Clinical Cancer Research</i> , <b>2002</b> , 8, 7-10	12.9	8
130	A murine preclinical syngeneic transplantation model for breast cancer precision medicine. <i>Science Advances</i> , <b>2017</b> , 3, e1600957	14.3	7
129	Prospective Clinical Sequencing of Adult Glioma. <i>Molecular Cancer Therapeutics</i> , <b>2019</b> , 18, 991-1000	6.1	7
128	Promising rationally derived combination therapy with PI3K and CDK4/6 inhibitors. <i>Cancer Cell</i> , <b>2014</b> , 26, 7-9	24.3	7
127	The impact of tumor heterogeneity on patient treatment decisions. <i>Clinical Chemistry</i> , <b>2013</b> , 59, 38-40	5.5	7
126	Unraveling the regulatory connections between two controllers of breast cancer cell fate. <i>Nucleic Acids Research</i> , <b>2014</b> , 42, 6839-49	20.1	7
125	Role of aberrant sialylation of chronic myeloid leukemia granulocytes on binding and signal transduction by chemotactic peptides and colony stimulating factors. <i>Leukemia and Lymphoma</i> , <b>1993</b> , 11, 79-90	1.9	7
124	The v-raf oncogene enhances tumorigenicity and suppresses differentiation in vivo in a rat hepatocyte cell line. <i>Carcinogenesis</i> , <b>1993</b> , 14, 669-74	4.6	7
123	Proteomic profiling of endometrioid endometrial cancer reveals differential expression of hormone receptors and MAPK signaling proteins in obese versus non-obese patients. <i>Oncotarget</i> , <b>2017</b> , 8, 106989-107001	3.3	7
122	Peritoneal Spread of Ovarian Cancer Harbors Therapeutic Vulnerabilities Regulated by FOXM1 and EGFR/ERBB2 Signaling. <i>Cancer Research</i> , <b>2020</b> , 80, 5554-5568	10.1	7
121	Modulation of the Hippo pathway and organ growth by RNA processing proteins. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2018</b> , 115, 10684-10689	11.5	7



120	The DNA Endonuclease Mus81 Regulates ZEB1 Expression and Serves as a Target of BET4 Inhibitors in Gastric Cancer. <i>Molecular Cancer Therapeutics</i> , <b>2019</b> , 18, 1439-1450	6.1	6
119	p85 $\beta$ regulates autophagic degradation of AXL to activate oncogenic signaling. <i>Nature Communications</i> , <b>2020</b> , 11, 2291	17.4	6
118	Comparison of Real-Time Fluorescence Confocal Digital Microscopy With Hematoxylin-Eosin-Stained Sections of Core-Needle Biopsy Specimens. <i>JAMA Network Open</i> , <b>2020</b> , 3, e200476	10.4	6
117	Glucose starvation induces mutation and lineage-dependent adaptive responses in a large collection of cancer cell lines. <i>International Journal of Oncology</i> , <b>2016</b> , 48, 67-72	4.4	6
116	Genomic copy number imbalances associated with bone and non-bone metastasis of early-stage breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2014</b> , 143, 189-201	4.4	6
115	The Successes and Failures of Policing Animal Rights Extremism in the UK 2004-2010. <i>International Journal of Police Science and Management</i> , <b>2013</b> , 15, 30-44	0.8	6
114	Systematic identification of combinatorial drivers and targets in cancer cell lines. <i>PLoS ONE</i> , <b>2013</b> , 8, e60339	3.7	6
113	Discussion: Metastasis and Angiogenesis in Epithelial Ovarian Cancer. <i>Gynecologic Oncology</i> , <b>2003</b> , 88, S37-S42	4.9	6
112	Introduction: Transmembrane signaling through hematopoietin receptors: interleukin-2 and erythropoietin. <i>Seminars in Immunology</i> , <b>1993</b> , 5, 297-298	10.7	6
111	Mechanical stress signaling in pancreatic cancer cells triggers p38 MAPK- and JNK-dependent cytoskeleton remodeling and promotes cell migration via Rac1/Cdc42/Myosin II. <i>Molecular Cancer Research</i> , <b>2021</b> ,	6.6	6
110	Mutant P53 induces MELK expression by release of wild-type P53-dependent suppression of FOXM1. <i>Npj Breast Cancer</i> , <b>2020</b> , 6, 2	7.8	6
109	Phase 1 trial of nelfinavir added to standard cisplatin chemotherapy with concurrent pelvic radiation for locally advanced cervical cancer. <i>Cancer</i> , <b>2021</b> , 127, 2279-2293	6.4	6
108	Modeling Heterogeneity of Triple-Negative Breast Cancer Uncovers a Novel Combinatorial Treatment Overcoming Primary Drug Resistance. <i>Advanced Science</i> , <b>2021</b> , 8, 2003049	13.6	6
107	Personalized Integrated Network Modeling of the Cancer Proteome Atlas. <i>Scientific Reports</i> , <b>2018</b> , 8, 14924	4.9	6
106	Molecular determinants of post-mastectomy breast cancer recurrence. <i>Npj Breast Cancer</i> , <b>2018</b> , 4, 34	7.8	6
105	Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanoma. <i>Oncogene</i> , <b>2021</b> , 40, 5590-5599	9.2	6
104	Identification and validation of a prognostic proteomic signature for cervical cancer. <i>Gynecologic Oncology</i> , <b>2019</b> , 155, 324-330	4.9	5
103	Analysis of the EDG2 receptor based on the structure/activity relationship of LPA. <i>Annals of the New York Academy of Sciences</i> , <b>2000</b> , 905, 279-81	6.5	5

102	Evidence that increases in lymphocyte tyrosine phosphorylation precede cardiac allograft rejection. Effects of cyclosporine and potential use in clinical management. <i>Transplantation</i> , <b>1994</b> , 58, 451-7	1.8	5
101	Interferon and phorbol esters down-regulate sIgM expression by independent pathways. <i>Journal of Cellular Physiology</i> , <b>1988</b> , 134, 245-52	7	5
100	Phase II study of the PARP inhibitor talazoparib (BMN-673) in advanced cancer patients with somatic alterations in BRCA1/2, mutations/deletions in PTEN or PTEN loss, a homologous recombination defect, mutations/deletions in other BRCA pathway genes and germline mutation S in BRCA1/2 (not breast or ovarian cancer).. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, TPS2617-TPS2617	2.2	5
99	Shrewd AKT regulation to survive. <i>Oncoscience</i> , <b>2014</b> , 1, 113-4	0.8	5
98	Predicting high-risk endometrioid carcinomas using proteins. <i>Oncotarget</i> , <b>2018</b> , 9, 19704-19715	3.3	5
97	Relationship Between Response and Dose in Published, Contemporary Phase I Oncology Trials. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2020</b> , 18, 428-433	7.3	5
96	Interleukin enhancer-binding factor 2 promotes cell proliferation and DNA damage response in metastatic melanoma. <i>Clinical and Translational Medicine</i> , <b>2021</b> , 11, e608	5.7	5
95	Using Reverse Phase Protein Array (RPPA) to Identify and Target Adaptive Resistance. <i>Advances in Experimental Medicine and Biology</i> , <b>2019</b> , 1188, 251-266	3.6	5
94	Cooperative Effect of Oncogenic and in an HGF-Dominant Environment in Breast Cancer. <i>Molecular Cancer Therapeutics</i> , <b>2019</b> , 18, 399-412	6.1	5
93	Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 6354-6365	12.9	5
92	Therapeutic Clues from an Integrated Omic Assessment of East Asian Triple Negative Breast Cancers. <i>Cancer Cell</i> , <b>2019</b> , 35, 341-343	24.3	4
91	Integrated transcriptomic-genomic tool Texomer profiles cancer tissues. <i>Nature Methods</i> , <b>2019</b> , 16, 401-406	40.6	4
90	Repurposing the Pap smear: one step closer to gynecologic cancer screening. <i>Science Translational Medicine</i> , <b>2013</b> , 5, 167ps1	17.5	4
89	Are oncogenes sufficient to cause human cancer?. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2010</b> , 107, 20599-600	11.5	4
88	Inhibition of stimulus-dependent epidermal growth factor receptor and transforming growth factor-alpha mRNA accumulation by the protein kinase C inhibitor staurosporine. <i>FEBS Letters</i> , <b>1989</b> , 243, 404-8	3.8	4
87	Abstract CT033: Safety and early efficacy signals for COTI-2, an orally available small molecule targeting p53, in a phase I trial of recurrent gynecologic cancer <b>2018</b> ,		4
86	Prevalence of incidental actionable germline mutations in 1,000 advanced cancer patients on a prospective somatic genomic profiling program.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 1510-1510	2.2	4
85	WEE1 inhibition induces anti-tumor immunity by activating ERV and the dsRNA pathway. <i>Journal of Experimental Medicine</i> , <b>2022</b> , 219,	16.6	4

84	Integrated Genomic Characterization of the Human Immunome in Cancer. <i>Cancer Research</i> , <b>2020</b> , 80, 4854-4867	10.1	4
83	Characterizing advanced breast cancer heterogeneity and treatment resistance through serial biopsies and comprehensive analytics. <i>Npj Precision Oncology</i> , <b>2021</b> , 5, 28	9.8	4
82	Clinical and Functional Characterization of Atypical / Mutations in Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 4587-4598	12.9	4
81	Expanded analysis of secondary germline findings from matched tumor/normal sequencing identifies additional clinically significant mutations. <i>JCO Precision Oncology</i> , <b>2019</b> , 3,	3.6	4
80	Analysis of Primary Tumor Specimens for Evaluation of Cancer Therapeutics. <i>Annual Review of Cancer Biology</i> , <b>2021</b> , 5, 39-57	13.3	4
79	MEK Inhibition Remodels the Immune Landscape of Mutant Tumors to Overcome Resistance to PARP and Immune Checkpoint Inhibitors. <i>Cancer Research</i> , <b>2021</b> , 81, 2714-2729	10.1	4
78	Credentialing Individual Samples for Proteogenomic Analysis. <i>Molecular and Cellular Proteomics</i> , <b>2018</b> , 17, 1515-1530	7.6	3
77	RADical response puts an exceptional responder in CHKmate: a synthetic lethal curative response to DNA-damaging chemotherapy?. <i>Cancer Discovery</i> , <b>2014</b> , 4, 988-90	24.4	3
76	Genome-wide perturbations by miRNAs map onto functional cellular pathways, identifying regulators of chromatin modifiers. <i>Npj Systems Biology and Applications</i> , <b>2015</b> , 1, 15001	5	3
75	Immunogold labeling of the low-affinity (55 kd) IL2 receptor on the surface of IL2 receptor-bearing cultured cells and mitogen-activated peripheral blood lymphocytes. <i>Journal of Leukocyte Biology</i> , <b>1990</b> , 48, 213-9	6.5	3
74	Chapter 19 Activation of Lymphocytes by Lymphokines. <i>Current Topics in Membranes and Transport</i> , <b>1990</b> , 35, 495-535		3
73	Genetic alterations and expression characteristics of ARID1A impact tumor immune contexture and survival in early-onset gastric cancer. <i>American Journal of Cancer Research</i> , <b>2020</b> , 10, 3947-3972	4.4	3
72	Costimulation of $\alpha$ CR and TLR7/8 promotes V $\alpha$ T-cell antitumor activity by modulating mTOR pathway and APC function. <b>2021</b> , 9,		3
71	Molecular Diagnostics in Cancer <b>2017</b> , 1-14		2
70	Impact of Cold Ischemic Time and Freeze-Thaw Cycles on RNA, DNA and Protein Quality in Colorectal Cancer Tissues Biobanking. <i>Journal of Cancer</i> , <b>2019</b> , 10, 4978-4988	4.5	2
69	Proteomics advances for precision therapy in ovarian cancer. <i>Expert Review of Proteomics</i> , <b>2019</b> , 16, 841-850		2
68	Development of prediction models for lymph node metastasis in endometrioid endometrial carcinoma. <i>British Journal of Cancer</i> , <b>2020</b> , 122, 1014-1022	8.7	2
67	Systems biology of breast cancer. <i>Current Breast Cancer Reports</i> , <b>2009</b> , 1, 238-245	0.8	2

66	General keynote: molecular therapeutics and pharmacogenomics. <i>Gynecologic Oncology</i> , <b>2003</b> , 88, S84-7; discussion S93-6	4.9	2
65	Differential Effects of Three Small Molecules Blocking Phosphatidylinositol-3 Kinase or AKT in Hodgkin Disease Cell Lines: Induction of Apoptosis and Cell Cycle Arrest.. <i>Blood</i> , <b>2004</b> , 104, 428-428	2.2	2
64	Clinical characteristics and survival outcomes in BRCA1-methylated epithelial ovarian cancer (Bmeth-OC): A pooled analysis of data for 1,278 patients across five studies.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 5526-5526	2.2	2
63	Profiling of immune features to predict immunotherapy efficacy.. <i>Innovation(China)</i> , <b>2022</b> , 3, 100194	17.8	2
62	Classification of Acute Myelogenous Leukemia (AML) Based on Patterns of Signal Transduction Pathway (STP) and Apoptosis Regulating Protein Activation Determined by Reverse Phase Proteins Arrays (RPPA).. <i>Blood</i> , <b>2005</b> , 106, 484-484	2.2	2
61	High Throughput Proteomic Analysis of 559 Acute Myelogenous Leukemia (AML) Patient Samples on a Single Slide Using Reverse Phase Proteins Arrays (RPPA): Analysis of Signal Transduction Pathway (STP) and Apoptosis Regulating Proteins.. <i>Blood</i> , <b>2006</b> , 108, 107-107	2.2	2
60	Candidate biomarker assessment for pharmacological response. <i>Translational Oncology</i> , <b>2020</b> , 13, 100830	4.9	2
59	Spatially interacting phosphorylation sites and mutations in cancer. <i>Nature Communications</i> , <b>2021</b> , 12, 2313	17.4	2
58	mi-IsoNet: systems-scale microRNA landscape reveals rampant isoform-mediated gain of target interaction diversity and signaling specificity. <i>Briefings in Bioinformatics</i> , <b>2021</b> , 22,	13.4	2
57	Reward Enhances Online Participants' Engagement With a Demanding Auditory Task. <i>Trends in Hearing</i> , <b>2021</b> , 25, 23312165211025941	3.2	2
56	Frequent post-operative monitoring of colorectal cancer using individualised ctDNA validated by multiregional molecular profiling. <i>British Journal of Cancer</i> , <b>2021</b> , 124, 1556-1565	8.7	2
55	copy number is a biomarker for response to combination WEE1-ATR inhibition in ovarian and endometrial cancer models. <i>Cell Reports Medicine</i> , <b>2021</b> , 2, 100394	18	2
54	MITI minimum information guidelines for highly multiplexed tissue images.. <i>Nature Methods</i> , <b>2022</b> , 19, 262-267	21.6	2
53	Anti-tumor Activity of a Mitochondrial Targeted HSP90 Inhibitor in Gliomas.. <i>Clinical Cancer Research</i> , <b>2022</b> ,	12.9	2
52	Identifying Abundant Immunotherapy and Other Targets in Solid Tumors: Integrating RNA-seq and Mass Spectrometry Proteomics Data Sets. <i>Cancer Journal (Sudbury, Mass)</i> , <b>2017</b> , 23, 108-114	2.2	1
51	Reply to M.P. Decatris et al. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 886	2.2	1
50	Unjustified blurring of the policing of protest or a vision of the way ahead?. <i>International Journal of Police Science and Management</i> , <b>2015</b> , 17, 128-133	0.8	1
49	p85 homomeric mutants: splitting away from the canonical path. <i>Molecular and Cellular Oncology</i> , <b>2015</b> , 2, e983388	1.2	1

48	Sparse Bayesian Graphical Models for RPPA Time Course Data <b>2012</b> , 2012, 113-117		1
47	Human hematopoietic cell express two forms of the cytokine receptor common gamma-chain (gamma c). <i>Cell Research</i> , <b>1997</b> , 7, 195-205	24.7	1
46	Overexpression of the Plasma Lysophospholipase D Autotaxin Reveals a Novel Pathway for Regulation of Hemostasis in Mice.. <i>Blood</i> , <b>2007</b> , 110, 3649-3649	2.2	1
45	Combined Homologous Recombination Deficiency (HRD) scores and response to neoadjuvant platinum-based chemotherapy in triple-negative and/or BRCA1/2 mutation-associated breast cancer.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 1018-1018	2.2	1
44	Multidimensional spatial characterization of the tumor microenvironment (TME) in synchronous melanoma metastases (SMM) to yield insights into mixed responses to therapy in metastatic melanoma (MM) patients (pts).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 9575-9575	2.2	1
43	Genomic-Glycosylation Aberrations in Tumor Initiation, Progression and Management. <i>AIMS Medical Science</i> , <b>2016</b> , 3, 386-416	0.4	1
42	Multimomics analysis of serial PARP inhibitor treated metastatic TNBC inform on rational combination therapies. <i>Npj Precision Oncology</i> , <b>2021</b> , 5, 92	9.8	1
41	Time Course Proteomic Profiling of Signal Transduction and Apoptosis Pathways in AML Survivor Cells Using Reverse Phase Protein Lysate Microarray (RPPA) Reveals Differential Effect of Time, Dose and Agent(s).. <i>Blood</i> , <b>2005</b> , 106, 1219-1219	2.2	1
40	Large-scale Characterization of Drug Responses of Clinically Relevant Proteins in Cancer Cell Lines		1
39	Adaptive response to BET inhibition induces therapeutic vulnerability to MCL1 inhibitors in breast cancer		1
38	Targeting ncRNAs in the 3q26.2 amplicon. <i>Oncoscience</i> , <b>2015</b> , 2, 671-2	0.8	1
37	Analysis of mutational and proteomic heterogeneity of gastric cancer suggests an effective pipeline to monitor post-treatment tumor burden using circulating tumor DNA. <i>PLoS ONE</i> , <b>2020</b> , 15, e0239966	3.7	1
36	Genomic, Transcriptomic, and Proteomic Profiling of Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 3243-3252	12.9	1
35	Genome-Wide Profiling of Acquired Uniparental Disomy Reveals Prognostic Factors in Head and Neck Squamous Cell Carcinoma. <i>Neoplasia</i> , <b>2019</b> , 21, 1102-1109	6.4	1
34	Ultrastructure of immunogenic cell death in vivo. <i>Microscopy and Microanalysis</i> , <b>2021</b> , 27, 1390-1391	0.5	1
33	Neural Crest-Like Stem Cell Transcriptome Analysis Identifies LPAR1 in Melanoma Progression and Therapy Resistance. <i>Cancer Research</i> , <b>2021</b> , 81, 5230-5241	10.1	1
32	A phase II study of MK-2206, an AKT inhibitor, in uterine serous carcinoma.. <i>Gynecologic Oncology Reports</i> , <b>2022</b> , 40, 100974	1.3	1
31	Whole-chromosome arm acquired uniparental disomy in cancer development is a consequence of isochromosome formation.. <i>Neoplasia</i> , <b>2022</b> , 25, 9-17	6.4	0

30	The roles of variants in pancreatic cancer development and their potential impact on cancer immunotherapy. <i>Autophagy</i> , <b>2020</b> , 16, 1923-1924	10.2	o
29	Uncoupling of gene expression from copy number presents therapeutic opportunities in aneuploid cancers. <i>Cell Reports Medicine</i> , <b>2021</b> , 2, 100349	18	o
28	Acquired Uniparental Disomy Regions Are Associated with Disease Outcome in Patients with Oral Cavity and Oropharynx But Not Larynx Cancers. <i>Translational Oncology</i> , <b>2020</b> , 13, 100763	4.9	o
27	TOP1 modulation during melanoma progression and in adaptive resistance to BRAF and MEK inhibitors. <i>Pharmacological Research</i> , <b>2021</b> , 173, 105911	10.2	o
26	BCL-XL blockage in TNBC models confers vulnerability to inhibition of specific cell cycle regulators. <i>Theranostics</i> , <b>2021</b> , 11, 9180-9197	12.1	o
25	An omic and multidimensional spatial atlas from serial biopsies of an evolving metastatic breast cancer.. <i>Cell Reports Medicine</i> , <b>2022</b> , 3, 100525	18	o
24	A multi-encoder variational autoencoder controls multiple transformational features in single-cell image analysis.. <i>Communications Biology</i> , <b>2022</b> , 5, 255	6.7	o
23	A functional genomic approach to actionable gene fusions for precision oncology.. <i>Science Advances</i> , <b>2022</b> , 8, eabm2382	14.3	o
22	Prospecting whole cancer genomes.. <i>Nature Cancer</i> , <b>2020</b> , 1, 273-275	15.4	
21	A Bayesian hierarchical model for inference across related reverse phase protein arrays experiments. <i>Journal of Applied Statistics</i> , <b>2014</b> , 41, 2483-2492	1	
20	Understanding the Functions of Lysophosphatidic Acid Receptors in Cancer <b>2013</b> , 641-659		
19	Mesenchymal Stem Cells Promote Survival of Leukemic Cells Via Integrin-Linked Kinase (ILK)-Dependent Akt and STAT3 Activation: Implications for Leukemia Therapy.. <i>Blood</i> , <b>2004</b> , 104, 3377-3377		
18	Protein Expression Signatures Determined by Reverse Phase Proteins Arrays (RPPA) Accurately Predict FLT3-ITD Mutation Status in AML.. <i>Blood</i> , <b>2007</b> , 110, 2398-2398	2.2	
17	Combination of Ionizing Radiation with Glutaminase Inhibition Improves Treatment Response in Head and Neck Squamous Cell Carcinoma. <i>FASEB Journal</i> , <b>2019</b> , 33, 495.9	0.9	
16	Molecular targets for epithelial ovarian cancer606-618		
15	Ultra-deep next-generation sequencing of plasma cell-free (cf) DNA from patients with advanced cancers.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, e22168-e22168	2.2	
14	Proteomic signatures of colorectal cancer to identify distinct and reproducible subgroups and to reflect prognosis.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 3612-3612	2.2	
13	Clinical outcomes based on multigene profiling in metastatic breast cancer patients.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 1524-1524	2.2	

12	Development of a public knowledgebase to facilitate decision support for clinical cancer genomics reporting and clinical trial enrollment.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, e22163-e22163	2.2
11	Enriched expression of PD-L1 and other immune targets after epithelial-mesenchymal transition (EMT) in squamous head and neck and lung cancers.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 6016-6016	2.2
10	Comparison of Mutation Profile Among Responders and Non-Responders in a Cohort of Patients with Relapsed/Refractory Myeloid Malignancies Treated with MEK 1/2 Inhibitor Trametinib. <i>Blood</i> , <b>2015</b> , 126, 1386-1386	2.2
9	The Novel Thiosemicarbazone Derivative Coti-2 Induces Mitochondrial Apoptosis in Acute Myeloid Leukemia Cells Via a p53-Independent Mechanism. <i>Blood</i> , <b>2016</b> , 128, 2757-2757	2.2
8	Small Molecule Inhibitors of HER2 Inhibit Proliferative Signaling and Promote Apoptosis in Ph+ ALL. <i>Blood</i> , <b>2011</b> , 118, 1397-1397	2.2
7	High risk CNIs, race and early stage breast cancer. <i>FASEB Journal</i> , <b>2013</b> , 27, 214.3	0.9
6	Tumor Therapy: In Situ Tumor Vaccination with Nanoparticle Co-Delivering CpG and STAT3 siRNA to Effectively Induce Whole-Body Antitumor Immune Response (Adv. Mater. 31/2021). <i>Advanced Materials</i> , <b>2021</b> , 33, 2170244	24
5	Analysis of mutational and proteomic heterogeneity of gastric cancer suggests an effective pipeline to monitor post-treatment tumor burden using circulating tumor DNA <b>2020</b> , 15, e0239966	
4	Analysis of mutational and proteomic heterogeneity of gastric cancer suggests an effective pipeline to monitor post-treatment tumor burden using circulating tumor DNA <b>2020</b> , 15, e0239966	
3	Analysis of mutational and proteomic heterogeneity of gastric cancer suggests an effective pipeline to monitor post-treatment tumor burden using circulating tumor DNA <b>2020</b> , 15, e0239966	
2	Analysis of mutational and proteomic heterogeneity of gastric cancer suggests an effective pipeline to monitor post-treatment tumor burden using circulating tumor DNA <b>2020</b> , 15, e0239966	
1	Identification of biomarkers of response to preoperative talazoparib monotherapy in treatment naïve gBRCA+ breast cancers.. <i>Npj Breast Cancer</i> , <b>2022</b> , 8, 64	7.8